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Ribonucleotide reductase inhibitors suppress
SAMHD1 ara-CTPase activity enhancing
cytarabine efficacy
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Abstract
The deoxycytidine analogue cytarabine (ara-C) remains the back-
bone treatment of acute myeloid leukaemia (AML) as well as other
haematological and lymphoid malignancies, but must be combined
with other chemotherapeutics to achieve cure. Yet, the underlying
mechanism dictating synergistic efficacy of combination
chemotherapy remains largely unknown. The dNTPase SAMHD1,
which regulates dNTP homoeostasis antagonistically to ribonu-
cleotide reductase (RNR), limits ara-C efficacy by hydrolysing the
active triphosphate metabolite ara-CTP. Here, we report that clini-
cally used inhibitors of RNR, such as gemcitabine and hydroxyurea,
overcome the SAMHD1-mediated barrier to ara-C efficacy in
primary blasts and mouse models of AML, displaying SAMHD1-
dependent synergy with ara-C. We present evidence that this is
mediated by dNTP pool imbalances leading to allosteric reduction
of SAMHD1 ara-CTPase activity. Thus, SAMHD1 constitutes a novel
biomarker for combination therapies of ara-C and RNR inhibitors
with immediate consequences for clinical practice to improve
treatment of AML.
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Introduction
Five-year overall survival (OS) in AML varies with age, ranging
from ~ 5% in elderly adults to more than 70% in children, causing
more than 10,000 deaths yearly in the United States alone (De
1 Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2 Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
3 Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
4 Department of Infectious Diseases, Virology, University Hospital Heidelberg, Heidelberg, Germany
5 Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
6 Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
7 Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
8 Department of Pharmacy, Kyung-Hee University, Seoul, South Korea
9 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
10 Department of Medical Sciences, Uppsala University, Uppsala, Sweden
11 Mechanistic Biology & Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
12 Paediatric Oncology, Theme of Children’s Health, Karolinska University Hospital Solna, Stockholm, Sweden
13 Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
*Corresponding author. Tel: +46 (0) 8 524 823 68; E-mail: sean.rudd@scilifelab.se
**Corresponding author. Tel: +46 (0) 8 524 832 04; E-mail: nikolas.herold@ki.se
†Deceased October 2017
‡These authors contributed equally to this work as first authors
§Present address: Research Institutes of Sweden (RISE), Material and Process Unit, Södertälje, Sweden
¶Present address: Heidelberg ImmunoTherapeutics GmbH, Heidelberg, Germany
ª 2020 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 12: e10419 | 2020 1 of 20
Kouchkovsky & Abdul-Hay, 2016). Standard chemotherapy in AML
treatment comprises anthracyclines, which are important for the
achievement of complete remission during induction courses (Fer-
nandez et al, 2009; Luskin et al, 2016), and the deoxycytidine
analogue cytarabine (ara-C). The latter constitutes the backbone of
high-dose remission consolidation therapy (Mayer et al, 1994;
Lowenberg, 2013). The interpatient susceptibility to high-dose ara-C
regimens is linked to the propensity of AML blasts to accumulate
the active triphosphate metabolite ara-CTP (Plunkett et al, 1985),
which causes DNA damage by perturbing DNA synthesis (Tsesmet-
zis et al, 2018). A main determinant for ara-CTP exposure, and thus
a key factor for ara-C efficacy, is the deoxynucleoside triphosphate
(dNTP) triphosphohydrolase SAM and HD domain-containing
protein-1 (SAMHD1), which we and others identified as an ara-
CTPase (Schneider et al, 2016; Herold et al, 2017a,b,c; Hollenbaugh
et al, 2017; Rudd et al, 2017; Rassidakis et al, 2018). Accordingly,
inactivation of SAMHD1 is a prime goal for rational improvement of
ara-C-based therapies; however, no valid clinical strategies exist,
nor are known efforts under development (Appendix Table S1).
Results
A phenotypic screen identifies gemcitabine as a SAMHD1-
dependent ara-C sensitiser
As in vitro and in silico-based approaches thus far
(Appendix Table S1) have not resulted in SAMHD1 inhibitors with
sufficient cellular activity, we embarked upon a cell-based pheno-
typic screening strategy to identify such compounds (overview in
Fig EV1A and B). We rationalised that a SAMHD1 inhibitor should
sensitise SAMHD1-proficient cells to ara-C toxicity, but not their
SAMHD1-deficient counterpart. We made use of our previously
described pairs of CRISPR/Cas9-engineered THP-1 cells that differ
with respect to their SAMHD1 status (Herold et al, 2017b) to
measure the inhibitory effect on cell proliferation of sub-lethal ara-C
concentrations in combination with a library of small molecules (for
technical information, see Appendix Supplementary Methods and
Appendix Fig S1). Briefly, in a first step, we screened a total of
33,467 compounds in SAMHD1-positive THP-1 cells in the presence
of a sub-lethal concentration of ara-C (Fig EV1A and B, and
Appendix Fig S1A and B). From the ~ 1,600 compounds that
showed an inhibition of cell proliferation of ≥ 30% in the presence
of ara-C, we then excluded compounds that were substantially toxic
even in the absence of ara-C (Appendix Fig S1C), before performing
concentration–response experiments for the remaining active
substances in the presence and absence of ara-C in both SAMHD1-
positive and SAMHD1-negative THP-1 cells (exemplified in
Fig EV1C). We identified SAMHD1-independent ara-C sensitisers,
such as the Wee1 inhibitor MK-1775, but also compounds demon-
strating SAMHD1-dependent ara-C sensitisation. Amongst these, we
were particularly intrigued by the clinically approved deoxycytidine
analogue gemcitabine (dF-dC; Fig EV1C). Surprisingly, neither dF-
dC itself nor its phosphorylated or deaminated metabolites inhibited
SAMHD1 activity in vitro (Fig EV1D), and treatment of cells with
dF-dC did not alter the thermal aggregation temperature (Tagg) of
SAMHD1 (Fig EV1E), arguing against binding of dF-dC or an active
metabolite thereof to SAMHD1 in living cells. These data indicate
that the SAMHD1-dependent ara-C sensitisation by dF-dC was not
due to a direct interaction with SAMHD1.
Apparent suppression of SAMHD1 ara-CTPase by dF-dC is a result
of RNR inhibition
The diphosphate metabolite of dF-dC (dF-dCDP) irreversibly inhi-
bits the key enzyme in de novo dNTP synthesis, RNR (Cerqueira
et al, 2007), which is consistent with an increased Tagg of RRM1
observed in dF-dC-treated cells (Fig EV1E). Given the allosteric
activation of SAMHD1 requires binding of (d)NTPs to two distinct
sites on each monomer, interactions that are necessary for forma-
tion of the catalytically competent tetramer (Ji et al, 2013; Zhu
et al, 2015), we hypothesised that alteration in the levels of these
endogenous activators through RNR inhibition might be responsi-
ble for the apparent ablation of SAMHD1 ara-CTPase activity by
dF-dC (Fig 1A). We thus predicted that other RNR inhibitors
(RNRi) should also sensitise cells to ara-C in a manner dependent
upon SAMHD1. To test this hypothesis, we treated a panel of
SAMHD1-proficient or SAMHD1-deficient haematological cancer
cell lines generated using CRISPR/Cas9 (Fig 1B) with a concentra-
tion–response matrix consisting of ara-C and an RNRi: either dF-
dC, hydroxyurea (HU) or triapine (3-AP; Figs 1C and EV2A); none
of which inhibited SAMHD1 in vitro (Fig EV1D). RNRi sensitised
SAMHD1-proficient THP-1 cells to ara-C in a concentration-depen-
dent manner, effectively reducing the half-maximal effective
concentration (EC50) for ara-C to that of their SAMHD1-deficient
counterpart. However, ara-C sensitisation was consistently not
observed in SAMHD1-deficient THP-1 cells (Fig 1C and D). Similar
results were obtained with additional SAMHD1-proficient and
SAMHD1-deficient cell lines of myeloid and lymphoid origin
(Fig EV2A). Importantly, ectopic expression of wild-type (WT)
SAMHD1, but not the catalytically inactive H233A mutant, could
restore the RNRi-mediated ara-C sensitisation in SAMHD1-deficient
THP-1 cells (Figs 1D and EV2A).
SAMHD1 expression levels dictate the extent of synergy between
ara-C and RNRi in cell lines
We subsequently performed drug synergy analyses using two
reference models, highest single agent (HSA) (Berenbaum, 1989)
(Fig EV2B) and zero interaction potency (ZIP) (Yadav et al, 2015)
(Fig 1E). The HSA model defines synergy as a combinatorial effect
that is larger than the individual drug effect observed at the same
concentration, whilst the ZIP model combines the widely used
Bliss independence and Loewe additivity models into a response
surface model that uses a delta score to characterise synergy.
According to both reference models, using the concentration–
response matrix summary score, the interaction between ara-C
and the RNRi was synergistic in all cell lines expressing dNTPase-
proficient SAMHD1 (Figs 1E and EV2B). Either the absence of
SAMHD1 protein or presence of catalytically inactive SAMHD1
abrogated synergy and significantly reduced the drug–drug interac-
tion to a near-additive response (Figs 1E and EV2B). Notably,
strongest synergy was observed in THP-1 cells, which express high
levels of SAMHD1, whilst in HL-60 cells, with much lower
SAMHD1 protein levels (Fig 1B), synergy was less pronounced
(Figs 1E and EV2B). Consistently, analysis of a broader panel of
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haematological cell lines revealed that synergy of dF-dC or HU
with ara-C significantly correlated with SAMHD1 protein abun-
dance (Fig 1F, Appendix Fig S2). In accordance, sub-lethal concen-
trations (EC10) of ara-C alone caused no induction of DNA damage
signalling in SAMHD1-proficient cells, whilst the combination with
sub-toxic doses of HU (Fig 1G) or dF-dC (Fig EV2C) led to robust
DNA damage (indicated by Chk1-pS345, Chk2-pT68 and cH2Ax)
and apoptotic (indicated by cleaved polyADP-ribose polymerase
[PARP]) signalling, to an extent similar to low-dose ara-C alone in
SAMHD1-deficient cells.
Allosteric inhibitors of RNR do not synergise with ara-C in a
SAMHD1-dependent manner
Purine nucleoside analogues are clinically combined with ara-C.
Some have also been shown to be substrates/activators of SAMHD1
(Arnold et al, 2015b; Herold et al, 2017a; Hollenbaugh et al, 2017;
Knecht et al, 2018) and, importantly, are documented to allosteri-
cally inhibit RNR as part of their cytotoxic mechanism (Aye &
Stubbe, 2011; Wisitpitthaya et al, 2016). We thus tested clofarabine
(Cl-F-ara-A), fludarabine (2-F-ara-A) and cladribine (2-CdA) for
their ability to synergise with ara-C. Unlike the previously tested
non-allosteric RNRi, allosteric RNRi Cl-F-ara-A and 2-F-ara-A
displayed only weak synergy with ara-C, whilst 2-CdA synergised
strongly, consistent with previous reports (Chow et al, 2003;
Stumpel et al, 2015). However, no SAMHD1-dependent drug–drug
interaction was observed across the cell line panel (Fig EV3A–D;
and possible reasons for this are detailed in the Discussion). The
Wee1 kinase inhibitor MK-1775, which we identified as a SAMHD1-
independent ara-C sensitiser (Fig EV1C), has been described as an
enhancer of ara-C toxicity before (Van Linden et al, 2013). We con-
firmed this in our drug combination matrix experiments, showing
that this synergy was largely independent of the SAMHD1 status,
even though the degree of synergy was more pronounced in some
SAMHD1-positive cell models (Appendix Fig S3). We also tested
histone deacetylase inhibitors (HDACi) in our drug combination
matrix experiments given HU can mimic some cellular effects of
HDACi at least in sickle cell disease (Cao, 2004). However, in
contrast to HU and other non-allosteric RNRi, only weak ara-C
sensitisation was observed, and this was independent of SAMHD1
status (Appendix Fig S4).
Given ara-C is routinely combined with an anthracycline during
AML treatment, we next performed drug combination matrix experi-
ments in which either daunorubicin or doxorubicin was added to
combinations of HU and ara-C. Whilst toxic concentrations of either
anthracycline decreased cell viability, the ability of HU to sensitise
cells to ara-C in SAMHD1-positive, but not SAMHD1-negative, cells
was preserved (Appendix Fig S5).
Taken together, these data indicate that a SAMHD1-dependent
synergism with ara-C is most pronounced with non-allosteric RNRi
such as dF-dC, HU and 3-AP, but not with allosteric purine nucle-
oside RNRi (e.g. Cl-F-ara-A, 2-F-ara-A and 2-CdA), the Wee1 kinase
inhibitor MK-1775, or HDACi. Of interest to potential clinical appli-
cation, the SAMHD1-dependent synergy of non-allosteric RNRi and
ara-C is not affected by the concomitant treatment with anthracy-
clines.
RNR inhibition relieves the SAMHD1-mediated barrier to ara-C
treatment in vivo
Next, we sought to investigate whether inhibition of RNR would
alleviate the SAMHD1-mediated resistance to ara-C in vivo. As HU
has been used in the treatment of AML for decades, is devoid of
dF-dC induced toxicity associated with repetitive dosing (O’Rourke
et al, 1994) and is furthermore cheap and highly accessible, we
decided to focus on this RNRi in two orthotopic mouse models of
AML. First, we injected either SAMHD1/ or SAMHD1+/+ THP-1
cell clones carrying a luciferase reporter into the tail vein of
NOD/SCID mice subsequent to treatment with PBS or ara-C and
HU, alone or in combination (Fig 2A, Appendix Fig S6). Irrespec-
tive of SAMHD1 status, mice treated with PBS only developed
signs of systemic disease after ~ 35 days and succumbed after a
median time span of 50 days. In SAMHD1-proficient AML, ara-C
treatment had no effect on survival as compared to PBS
treatment, but ara-C significantly prolonged survival in SAMHD1-
deficient AML mice, resulting in a median survival of 68 days
◀
Figure 1. RNR inhibitor and ara-C synergy are dependent upon functional SAMHD1 in cancer cell models.
A Schematic detailing of proposed interplay between RNR and SAMHD1.
B Immunoblot of lysates prepared from the indicated SAMHD1-proficient (+/+), SAMHD1-deficient (/) and rescue (WT, H233A) cell line pairs with the indicated
antibodies. Representative of 2 independent experiments.
C Proliferation inhibition analysis of ara-C and RNRi combination treatment in SAMHD1+/+ or / THP-1 cells. Error bars indicate SEM of two (HU and dF-dC) or three
(3-AP) independent experiments, each performed in duplicate.
D Ara-C EC50 values plotted as a function of RNRi concentration in SAMHD1
+/+, / and rescue (WT, H233A) THP-1 cell line pairs. EC50 values in the absence of RNRi are
indicated by the black and red dotted line. Error bars indicate SEM of two (HU and dF-dC) or three (3-AP) independent experiments, each performed in duplicate.
E Drug synergy plots for ara-C and the indicated RNRi in SAMHD1+/+, / and rescue (WT, H233A) cell line pairs. Each data point indicates an average delta score from a
single dose–response matrix experiment performed in duplicate. Zero, > 0 or < 0 corresponds to additive, synergy or antagonism, respectively, whilst > 5 indicates
strong synergy. The horizontal line and the error bars indicate the mean and SD, respectively, and statistical significance was determined using a two-tailed unpaired
t-test: ns, not significant, P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
F Spearman correlations of relative SAMHD1 protein abundance and synergy delta scores for ara-C versus HU or dF-dC in a panel (n = 9) of haematological cancer cell
lines. Error bars indicate SEM. Each data point corresponds to SAMHD1 protein levels determined by immunoblot analysis (n = 4 for each cell line, representative blot
shown in Appendix Fig S2) and an average delta score from repeated dose–response matrix experiments each performed in triplicate: THP-1, n = 4; HuT-78, n = 2;
HL-60/iva, n = 1; KBM-7, n = 2 (HU) and 3 (dF-dC); K562, n = 3 (HU) and 4 (dF-dC); CCRF-CEM, n = 3 (HU) and 4 (dF-dC); MV-4-11, n = 2 (HU) and 3 (dF-dC); Jurkat,
n = 2 (HU) and 3 (dF-dC); MOLT-4, n = 2 (HU) an 3 (dF-dC).
G Immunoblot analysis of lysates prepared from SAMHD1+/+ or / THP-1 cells treated for 24 h with ara-C and HU, as indicated. Representative of 3 independent
experiments.
Source data are available online for this figure.
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(P = 0.0018), consistent with our previously published results
(Herold et al, 2017a,b,c). Combination treatment of HU and ara-C
in mice xenotransplanted with SAMHD1-proficient THP-1 cells
resulted in a median survival of 64 days, significantly better than
ara-C treatment alone (P = 0.0141). These results were recapitu-
lated in a second experiment using SAMHD1-proficient and
SAMHD1-deficient HL60/iva clones (Fig 2B, Appendix Fig S7). In
both experiments, combination treatment caused transient weight
loss in mice (Appendix Figs S6D and E, and S7D and E). Of note,
in both studies, a trend towards improved survival was observed
in mice with SAMHD1-deficient AML cells when comparing
combination treatment with ara-C treatment alone (P = 0.0737
and P = 0.0893).
To complement this dataset, we performed an additional experi-
ment using the RNRi dF-dC in the THP-1 SAMHD1+/+ AML mouse
model. To mitigate dF-dC toxicity associated with repetitive dosing
as described above, we only administered two doses of dF-dC on
days 1 and 3 of the 5-day treatment regimen. Median survival in this
experiment did not significantly differ for animals treated with PBS,
ara-C or dF-dC (44, 47 and 49.5 days, respectively, Fig 2C,
Appendix Fig S8). However, combination of ara-C with dF-dC led to
a median survival of 65 days, significantly longer as compared to
ara-C or dF-dC alone (P = 0.0014, and P = 0.0097, respectively,
Fig 2C). Also in this experiment, transient weight loss was observed
in the combination treatment (Appendix Fig S8B). Taken together,
these data demonstrate that combining the RNRi HU or dF-dC with
ara-C can overcome the SAMHD1-mediated barrier to ara-C efficacy
in vivo.
As xenotransplantation of human cells requires the use of
immunocompromised mice, we next employed a syngeneic murine
AML model using myeloid precursors transformed by transduction
with the fusion gene MLL-AF9 (Xiao et al, 2018) to further assess
the combination of ara-C and HU. MLL-AF9-transformed blasts
showed detectable expression of SAMHD1 and, in accordance,
could be moderately sensitised to ara-C by HU in vitro
(Appendix Fig S9). Median survival for this aggressive AML model
treated with normal saline (NS, vehicle), HU, ara-C or the combi-
nation of ara-C and HU was 6, 8, 12 and 14 days post-treatment,
respectively (Fig 2D). Significance in the difference of survival was
reached comparing ara-C and HU with vehicle (P = 0.0026), but
not comparing ara-C only or HU only with vehicle (P = 0.0995,
and P = 0.2252, respectively). This model allowed the parallel
study of myelotoxicity, which is relevant as both ara-C and HU
are myelotoxic drugs, and excessive bone marrow toxicity might
complicate the use of this combination treatment in clinical
settings. On day 1 post-chemotherapy, whilst both ara-C and ara-C
plus HU significantly reduced the total white blood count (WBC),
red blood cell count (RBC), haemoglobin and mean corpuscular
volume (MCV) of erythrocytes in peripheral blood as compared to
vehicle, no significant differences in these parameters were
observed comparing ara-C with ara-C and HU (Fig EV4A–D). In
addition, mean corpuscular haemoglobin (MCH) and platelet
counts were not affected adversely (Fig EV4E and F). Similarly, no
significant differences in bone marrow cellularity and spleen
weight at sacrifice were measured (Fig EV4G and H). This
suggests that myelotoxicity of ara-C and HU combination therapy
is not in excess of myelotoxicity of ara-C alone in immunocompe-
tent mice.
SAMHD1 expression levels dictate the extent of synergy between
ara-C and RNRi in primary patient-derived AML blasts
To determine whether the RNRi HU and dF-dC synergise with ara-
C in primary patient cells, we subjected adult (n = 8) and paedi-
atric (n = 8) AML blasts ex vivo to concentration–response
matrices of ara-C and HU or dF-dC. In the majority of patient
samples, with increasing doses of either dF-dC or HU, increased
sensitivity to ara-C was observed (Appendix Fig S10A and B).
Accordingly, determination of summary synergy scores using both
ZIP and HSA reference models indicated synergy of RNRi and ara-
C in the majority of samples (Fig 3A, Appendix Fig S10D). After
performing quantitative immunoblotting of SAMHD1 from lysates
prepared from the same patient blasts (Appendix Fig S10C), we
revealed that the extent of synergy using the ZIP reference model
significantly correlated with the abundance of SAMHD1 protein
(r = 0.4189; P = 0.0466; Fig 3B). A similar trend was observed
using the HSA model (Appendix Fig S10E). To further interrogate
the dependence of RNRi and ara-C synergy upon catalytically
active SAMHD1, we pre-treated patient AML blasts ex vivo with
virus-like particles (VLPs) either containing (X) or lacking (dX) the
lentiviral protein Vpx that depletes SAMHD1 by targeting it for
proteasomal degradation, prior to incubating them with ara-C and
RNRi concentration–response matrices. As demonstrated previ-
ously (Hrecka et al, 2011; Laguette et al, 2011; Herold et al,
2017b), Vpx treatment efficiently depleted SAMHD1 protein
(Fig 3C and E, Appendix Fig S10C) and, in line with our data in
cancer cell lines, completely abolished the RNRi-mediated sensiti-
sation to ara-C toxicity (Fig 3D and F). With increasing doses of
HU or dF-dC, concentration-dependent decreases in ara-C EC50
values were observed in the majority of samples evaluated, in
some cases reducing the ara-C EC50 values by two orders of
magnitude (Fig 3F). Comparison of the summary synergy scores of
those samples treated with Vpx-VLPs or control VLPs, using the
ZIP reference model, revealed a significant (P = 0.0046) reduction
in the extent of synergy, from a median delta score of 8.5 to 3.05
(Fig 3G), and a similar result was obtained using the HSA refer-
ence model (Appendix Fig S10F). These data are in agreement
with the results obtained in cancer cell lines (Fig 1F), demonstrat-
ing that the level of SAMHD1 dictates the extent of RNRi and ara-
C synergy.
High expression of SAMHD1 and RNR subunits correlates with
reduced survival in AML patients
Given that inhibitors of RNR activity modulated ara-C toxicity in a
SAMHD1-dependent manner, we next evaluated whether expres-
sion levels of RNR genes impact the survival of AML patients
treated with ara-C. We re-assessed clinical data and mRNA expres-
sion levels of patients treated with ara-C from the publicly avail-
able adult de novo and paediatric AML databases from the The
Cancer Genome Atlas (TCGA) and the Therapeutically Applicable
Research To Generate Effective Treatments (TARGET) projects,
respectively, as described previously (Herold et al, 2017b). Only
RRM2B encoding the p53-induced small subunit of RNR showed
statistically significantly higher hazard ratios (HRs) for event-free
(EFS) and OS for ara-C-treated AML patients in univariable Cox
proportional hazard regression analyses. However, when analysed
ª 2020 The Authors EMBO Molecular Medicine 12: e10419 | 2020 5 of 20
Sean G Rudd et al EMBO Molecular Medicine
in the same model as RRM1, RRM2 and RRM2B, respectively
(Table 1), SAMHD1 showed slight increases of HRs in multivari-
able regression in particular for OS after 18 and 12 months for the
TCGA and TARGET cohorts, respectively. Importantly, significance
was maintained despite a loss of power as compared to univariable
analyses. This is consistent with the notion that the interplay
between SAMHD1 and RNR is important for the efficacy of ara-C
therapies.
RNRi invert the ratio of dCTP-to-dATP concentrations and
activate dCK
Thus far, we have established that RNRi can sensitise cells to ara-
C in a SAMHD1-dependent manner, albeit without directly inhibit-
ing SAMHD1. The activity of SAMHD1 can be regulated by post-
translational modifications, and so we speculated this could be the
cause of the apparent loss of ara-CTPase activity. Reactive oxygen
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Figure 2. RNR inhibition overcomes the SAMHD1-mediated barrier to ara-C in AML mouse models.
A Kaplan–Meier analysis of NOD/SCID mice injected i.v. with luciferase-expressing SAMHD1+/+ or / THP-1 cell clones (day 0) and treated with ara-C and/or HU as
indicated (day 6). n = 6 per treatment group. For further data and analysis, see Appendix Fig S6.
B Kaplan–Meier analysis of NOD/SCID mice injected i.v. with luciferase-expressing SAMHD1+/+ or / HL-60/iva cell clones (day 0) and treated with ara-C and/or HU as
indicated (day 6). n = 6 per treatment group. For further data and analysis, see Appendix Fig S7.
C Kaplan–Meier analysis of NOD/SCID mice injected i.v. with luciferase-expressing SAMHD1+/+ THP-1 cell clone (day 0) and treated with ara-C and/or dF-dC as
indicated (day 6). n = 7 per treatment group. For further data and analysis, see Appendix Fig S8.
D Kaplan–Meier analysis of CD45.2 C57BL/6J mice injected i.v. with murine MLL-AF9-transformed AML blasts (day 0) and treated with ara-C and/or HU days 20–24.
n = 5 per treatment group, except for vehicle (n = 4). For further data and analysis, see Appendix Figs S8 and S9.
Data information: Tick marks indicate censored animals. Statistical significance determined using Mantel–Cox log-rank test: ns, not significant, P ≥ 0.05; *P < 0.05;
**P < 0.01.
Source data are available online for this figure.
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Figure 3. RNR inhibition enhances ara-C efficacy in primary patient AML blasts in a SAMHD1-dependent manner.
A Drug synergy plots for ara-C and HU or dF-dC in primary patient-derived AML blasts. Each data point indicates an average delta score from a single patient sample
subjected to a dose–response matrix experiment performed in triplicate, n = 16 for HU and n = 9 for dF-dC. Zero, > 0 or < 0 corresponds to additive effects,
synergy or antagonism, respectively, whilst > 5 indicates strong synergy. Median, upper and lower quartiles, and range of delta scores are indicated by box-and-
whisker plots. For proliferation inhibition curves for each sample, see Appendix Fig S10A and B, and for patient characteristics, see Appendix Table S2.
B Pearson correlation of relative SAMHD1 protein abundance and synergy delta scores for ara-C and HU or dF-dC in primary patient-derived AML blasts (n = 23). For
immunoblot analysis of SAMHD1 protein abundance, see Appendix Fig S10C.
C–F Immunoblot of primary patient-derived AML blasts treated with control (dX) or Vpx-containing (X) virus-like particles (VLPs): patient A2953 (C), ALG17_001 (E).
Accompanying proliferation inhibition analysis of ara-C and indicated RNRi combination in these samples: patient A2953 (D), ALG17_001 (D). Error bars indicate SD
of single experiment performed in triplicate.
G Paired drug synergy plot for ara-C and RNRi (HU, n = 7; dF-dC, n = 5) in primary patient-derived AML blasts pre-treated with control (dX) or Vpx-containing (X)
VLPs. Zero, > 0 or < 0 corresponds to additive effects, synergy or antagonism, respectively, whilst > 5 indicates strong synergy and < 5 indicates strong antagonism.
Each data point indicates an average delta score from a single patient sample subjected to a dose–response matrix experiment performed in triplicate. Statistical
testing was performed using two-way ANOVA.
Source data are available online for this figure.
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species (ROS) can reversibly oxidise cysteine residues in SAMHD1
resulting in inhibition of tetramerisation and catalysis (Mauney
et al, 2017), and RNR inhibition is known to induce ROS (Somya-
jit et al, 2017; Patra et al, 2019). However, pre-treatment of cells
with the ROS scavenger N-acetylcysteine (NAC) had no effect on
synergy between ara-C and HU (Appendix Fig S11). Threonine
phosphorylation at position 592 (T592) of SAMHD1 by cyclin-
dependent kinases 1 and 2 (Cdk1/2) has also been implicated in
regulating catalytic activity, in particular when dNTP levels are
low (Arnold et al, 2015a; Yan et al, 2015). RNR inhibition can
perturb cell cycle progression and thereby affect expression and/or
activity of Cdk1/2 (Rieber & Rieber, 1994; Tanguay & Chiles,
1994; Rodriguez-Bravo et al, 2007). However, expression of a
phosphomimetic T592E or phosphorylation-null T592A mutant
SAMHD1 in SAMHD1-deficient THP-1 cells had little effect upon
the ability of HU or dF-dC to sensitise these cells to ara-C
(Appendix Fig S11).
Next, we hypothesised that the apparent loss of SAMHD1 ara-
CTPase activity may be due to perturbation of dNTP pools, which
are required for allosteric activation of the ara-CTPase activity of
SAMHD1 (Fig 1A). Depletion of dNTP pools might push the effec-
tive concentrations of allosteric activators at the second allosteric
site (AS2) below a threshold required to maintain the catalytically
competent tetrameric conformation. Hence, we investigated whether
the relative composition of monomers, dimers and tetramers of
SAMHD1 was affected by inhibition of RNR using in vivo cross-
linking experiments. Surprisingly, no gross changes in the propor-
tion of tetrameric SAMHD1 were observed in HU- or dF-dC-treated
cells (Fig EV5A–D). These data are supported also by the lack of a
substantial change in the Tagg of SAMHD1 in HU- or dF-dC-treated
Table 1. Hazard ratios (HR) for mRA levels of SAMHD1 and RRM1, RRM2 and RRM2B (all log-transformed using the natural logarithm) in univariable
regression as well as hazard ratios for SAMHD1 in multivariable regression models in ara-C-treated AML patients.
TCGA cohort
mRNA
EFSa,h,i
completec
EFS
18 monthsd
OSb,h,i
complete
OS
18 months
Univariable
SAMHD1 1.16 (1.00–1.34; 0.0419) 1.23 (1.05–1.46; 0.0101) 1.15 (0.99–1.34; 0.0628) 1.25 (1.03–1.53; 0.0257)
RRM1e 1.55 (0.99–2.43; 0.0553) 1.42 (0.87–2.33; 0.1652) 1.58 (0.99–2.50; 0.0504) 1.49 (0.83–2.66; 0.1833)
RRM2f 1.23 (0.89–1.73; 0.2065) 1.25 (0.88–1.80; 0.2142) 1.11 (0.78–1.57; 0.5727) 1.15 (0.75–1.76; 0.5206)
RRM2Bg 1.69 (0.95–3.00; 0.0753) 1.59 (0.85–2.99; 0.1459) 1.86 (1.03–3.36; 0.0361) 1.33 (0.64–2.81 (0.4424)
Multivariable (SAMHD1)
SAMHD1 + RRM1 1.18 (1.02–1.36; 0.0293) 1.25 (1.06–1.48; 0.0080) 1.17 (1.00–1.37; 0.0442) 1.27 (1.04–1.56; 0.0209)
SAMHD1 + RRM2 1.15 (0.99–1.33; 0.0612) 1.23 (1.04–1.45; 0.0158) 1.15 (0.98–1.34; 0.0714) 1.25 (1.02–1.53; 0.0299)
SAMHD1 + RRM2B 1.15 (1.00–1.33; 0.0455) 1.23 (1.04–1.45; 0.0116) 1.15 (0.99–1.33; 0.0603) 1.25 (1.02–1.52; 0.0286)
SAMHD1 + RRM1 + RRM2B 1.17 (1.01–1.35; 0.0329) 1.24 (1.05–1.46; 0.0094) 1.16 (1.00–1.36; 0.0458) 1.27 (1.03–1.55; 0.0225)
TARGET cohort
mRNA
EFS
complete
EFS
12 monthsd
OS
complete
OS
12 months
Univariable
SAMHD1 1.00 (0.87–1.17; 0.9547) 1.01 (0.83–1.23; 0.9321) 0.96 (0.80–1.16; 0.6870) 1.54 (1.02–2.31; 0.0381)
RRM1 1.38 (0.91–2.08; 0.1301) 1.49 (0.84–2.63; 0.1724) 1.49 (0.89–2.51; 0.1332) 0.91 (0.31–2,67; 0.8567)
RRM2 1.09 (0.90–1.32; 0.3671) 1.19 (0.90–1.58; 0.2224) 1.09 (0.85–1.40; 0.4886) 1.41 (0.80–2.48; 0.2368)
RRM2B 1.39 (1.04–1.85; 0.0279) 1.28 (0.86–1.91; 0.2176) 1.47 (1.01–2.14; 0.0416) 0.79 (0.37–1.68; 0.5406)
Multivariable (SAMHD1)
SAMHD1 + RRM1 1.01 (0.87–1.17; 0.9294) 1.02 (0.83–1.24; 0.8700) 1.01 (0.87–1.17; 0.9294) 1.54 (1.02–2.31; 0.0384)
SAMHD1 + RRM2 0.97 (0.82–1.14; 0.7188) 0.95 (0.77–1.18; 0.6555) 0.97 (0.82–1.14; 0.7189) 1.48 (0.95–2.29; 0.0803)
SAMHD1 + RRM2B 1.09 (0.92–1.28; 0.3157) 1.07 (0.86–1.34; 0.5267) 1.09 (0.92–1.28; 0.3157) 1.56 (1.01–2.41; 0.0461)
SAMHD1 + RRM1 + RRM2B 1.08 (0.91–1.27; 0.3587) 1.06 (0.86–1.32; 0.5721) 1.08 (0.92–1.27; 0.3587) 1.56 (1.01–2.43; 0.0466)
aEvent-free survival.
bOverall survival.
cComplete follow-up period.
dFollow-up censored after the first 18 or 12 months after diagnosis.
eRibonucleoside-diphosphate reductase (large) subunit M1.
fRibonucleoside-diphosphate reductase (small) subunit M2.
gRibonucleoside-diphosphate reductase (small) subunit M2B.
hAdjusted for age, sex and cytogenetic risk group.
iShown are hazard ratios, 95% confidence intervals and P-values calculated with Wald test. Bold text indicates P-values < 0.05.
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cells (Fig EV5E–F), which would otherwise indicate a change in
oligomeric composition, as demonstrated by an oligomerisation-
dead mutant of SAMHD1 with a greatly reduced Tagg (Fig EV5G).
Therefore, we concluded that treatment of cells with an RNRi did
not greatly alter the oligomeric structure of SAMHD1. This argues
against a depletion of allosteric AS2 activators as the underlying
cause of the indirect loss of ara-CTPase activity observed following
RNR inhibition.
To assess the effects of RNRi on dNTP pools directly, THP-1 cells
were treated with low doses of either HU or 3-AP, and individual
dNTP species measured using a primer extension assay (Diamond
et al, 2004). Differential effects on purine and pyrimidine dNTP
pools were observed (Appendix Fig S12A–D); irrespective of treat-
ment, dTTP was clearly the most abundant dNTP species, whilst the
least abundant under untreated conditions, dCTP, reached similar
levels as dGTP and surpassed those of dATP following RNRi treat-
ment. As a net result, dCTP-to-dATP ratios were not only increased
threefold to sixfold, but also inverted from 0.6  0.1 to up to
3.5  0.8 by RNRi treatment (Fig 4A, Appendix Fig S12A–D). Next,
we performed combination experiments with ara-C and either HU,
3-AP or dF-dC using liquid chromatography–mass spectrometry (LC-
MS/MS) (Fromentin et al, 2010)—as this allowed the incorporation
of ara-C and dF-dC into the experiments (whose triphosphate
metabolites would interfere with the primer extension assay). Intra-
cellular amounts of ara-CTP when adding an RNRi to ara-C in
SAMHD1-proficient THP-1 cells were significantly increased by a
factor of ~ 4 as compared to treatment with ara-C alone, almost
achieving levels of ara-CTP in SAMHD1-deficient THP-1 cells treated
with ara-C (Fig 4B). This correlated with an increased dCTP-to-
dATP ratio in RNRi-treated cells that was unaffected by treatment
with ara-C alone (Fig 4B).
As RNRi HU, dF-dC and 3-AP inhibited de novo synthesis of
dNTPs, we hypothesised that the differential net effects on dNTP
species might stem from a concomitant activation of the dNTP
salvage pathway. Consistent with this, RNRi treatment led to an
increase in activating phosphorylation of salvage enzyme dCK at
serine-74 ~ 8- to 20-fold (Fig 4C).
dCTPaS-activated SAMHD1 is a poor ara-CTPase
Thus far, we have established that RNRi do not cause a net reduc-
tion of SAMHD1 tetramers and lead to dNTP imbalances rather
than absolute depletion that nonetheless correlated with a
concomitant increase in ara-CTP. Next, we investigated whether
the ara-CTPase activity of SAMHD1 is differentially activated by
the dNTP occupying AS2, which could explain the presence of a
tetrameric yet ara-CTPase-deficient SAMHD1. Conducting biochem-
ical experiments, we incubated recombinant SAMHD1 with satu-
rating concentrations of GTP (as an allosteric regulator for AS1),
ara-CTP (as a substrate for the catalytic site) and a titration of a
series of dNTPaS, i.e. non-hydrolysable dNTP analogues intended
as allosteric regulators for the AS2 site. Whilst dGTPaS, dATPaS
and dTTPaS could activate the hydrolysis of ara-CTP, dCTPaS,
even at concentrations up to 20- to 100-fold higher than needed
for saturation of ara-CTPase activity with the other dNTP analo-
gues, could not (Fig 4D). In contrast, incubation of SAMHD1 with
equivalent concentrations of dCTP could activate the dCTPase
activity of SAMHD1, indicating that this concentration of dCTP
can induce oligomerisation (Appendix Fig S13A). In line with this,
thermal shift assays of recombinant SAMHD1 revealed little dif-
ference in thermostability profiles between SAMHD1 incubated
with either GTP and dCTPaS, or GTP and dATPaS (Appendix Fig
S13B and C). Taken together, we propose a model in which inhi-
bition of RNR leads to an imbalance of the dNTP pool, specifically
an inversion of the dCTP-to-dATP ratio, causing a switch in the
dNTP occupying the AS2 site that results in reduced ara-CTPase
activity of SAMHD1 (Fig EV5H).
Discussion
The deoxycytidine analogue ara-C remains the backbone treatment
against AML (Mayer et al, 1994; Lowenberg, 2013). Clinical
responses to ara-C correlate with accumulation of the active
metabolite ara-CTP in AML cells (Plunkett et al, 1985), which is
strongly regulated by the dNTPase SAMHD1 (Schneider et al, 2016;
Herold et al, 2017a,b,c; Hollenbaugh et al, 2017; Rudd et al, 2017;
Rassidakis et al, 2018). Thus, inactivation of SAMHD1 ara-CTPase
is of immediate interest to rationally improve ara-C therapies. In this
study, we embarked upon a phenotypic screening strategy to iden-
tify small molecules that could sensitise a SAMHD1-proficient AML
cell line to ara-C but not their SAMHD1-deficient counterpart. We
identified the deoxycytidine analogue dF-dC, clinically used to treat
a range of solid malignancies (Toschi et al, 2005), as one such mole-
cule. Subsequently, we show that the ability of this molecule to
sensitise AML cells to ara-C in a SAMHD1-dependent manner is not
through direct interaction with SAMHD1, but rather inhibition of its
known target RNR. Accordingly, other RNRi such as HU and 3-AP,
clinically used in AML (Mamez et al, 2016) and being evaluated in a
number of clinical trials (Toschi et al, 2005), respectively, also
displayed this phenomenon. We further demonstrate that these
effects are restricted to non-allosteric RNRi inhibitors as known
allosteric inhibitors Cl-F-ara-A, F-ara-A and 2-CdA did not display
SAMHD1-dependent synergy with ara-C (see below for further
details). The SAMHD1-dependent synergy for non-allosteric RNRi
was observed in multiple cancer cell lines and patient-derived AML
blasts and could be mechanistically linked to increasing intracellular
ara-CTP concentrations, leading to induced DNA damage and apop-
tosis. These pharmacologic effects correlated with SAMHD1 protein
abundance and, furthermore, could overcome the SAMHD1-
mediated barrier to ara-C efficacy in AML xenograft mouse models.
RNRi could lead to post-translational modification of SAMHD1:
increased cysteine oxidation through ROS or altered T592 phospho-
rylation via Cdk1/2 inhibition. Indeed, oxidation can inactivate
SAMHD1 (Mauney et al, 2017), and T592 phosphorylation has been
reported to alter SAMHD1’s substrate specificity (Jang et al, 2016).
However, our experiments with a ROS scavenger and SAMHD1
phosphomutants did not implicate these modifications in RNRi-
mediated ara-C sensitisation.
Small-molecule SAMHD1 inhibitors have been reported previ-
ously (Seamon et al, 2014; Seamon & Stivers, 2015; Hollenbaugh
et al, 2017) (Appendix Table S1); however, whilst these molecules
inhibit recombinant SAMHD1 in vitro, they have no demonstrated
cell activity. More recently, a number of diverse FDA-approved
drugs have been reported to inhibit hydrolysis of dGTP at micromo-
lar concentrations in vitro, none of which inhibited dCTP hydrolysis,
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however (Mauney et al, 2018) (Appendix Table S1). Given the
shortage of suitable small-molecule tools for cellular studies, we
have alternatively proposed using Vpx as a biologic SAMHD1 inhi-
bitor (Herold et al, 2017b). Also, this approach has limitations, as
we discussed (Herold et al, 2017a). Importantly, here, we have
demonstrated that drugs already in clinical use can be used to indi-
rectly target SAMHD1 activity towards ara-CTP and thereby possibly
overcome this barrier to ara-C efficacy in AML treatment. Critically,
one of these, HU, is already used to treat AML, thus facilitating rapid
translation of these findings to the clinic.
Synergy between RNRi and ara-C has been reported previously
in vivo as well as in ex vivo experiments of primary patient blasts and
in cell lines (Plagemann et al, 1978; Walsh et al, 1980; Streifel &
Howell, 1981; Howell et al, 1982; Rauscher & Cadman, 1983; Tanaka
et al, 1985; Kubota et al, 1988, 1989; Gandhi & Plunkett, 1990; Bhalla
et al, 1991; Colly et al, 1992; Santini et al, 1996; Iwasaki et al, 1997;
Freund et al, 1998; Heinemann et al, 1998; Ahlmann et al, 2001;
Hubeek et al, 2004; Sigmond et al, 2007) (for further detail, see
Appendix Table S3). Our study provides a mechanistic framework of
this synergy in its dependence on functional SAMHD1 and expression
levels thereof. Indeed, synergy of RNRi and ara-C, as well as an
increase in intracellular ara-CTP levels, was predominantly reported
in cell lines now known to be SAMHD1-positive and absent in
SAMHD1-negative cell lines (Appendix Table S3), which is supported
by the data presented here.
RNR is critical for the de novo production of dNTPs that in turn
allosterically regulate SAMHD1 activity. This is particularly relevant
for ara-CTP given this nucleotide species is not an allosteric
◀
Figure 4. dCTPaS-activated SAMHD1 is a poor ara-CTPase.
A Intracellular dNTP measurements using a primer extension assay in
SAMHD1+/+ THP-1 cells treated for 4 or 24 h with either 50 lM HU (middle
panel) or 2.5 nM 3-AP (right panel), ratios of dCTP-to-dATP were calculated.
Bars indicate mean values of three independent experiments; error bars
indicate SEM. Statistical analyses were done using unpaired two-tailed
t-tests: **P < 0.01. For absolute values of dNTP pool measurements, see
Appendix Fig S11.
B Intracellular relative ara-CTP levels (upper panel) and dCTP:dATP ratio
(lower panel) in the indicated cell lines following the indicated treatments
determined using HPLC-MS/MS. SAMHD1/ THP-1 cells were treated with
500 nM ara-C, and SAMHD1+/+ THP-1 cells were treated with either
solvent, 500 nM ara-C or a combination of 500 nM ara-C and an RNRi (HU,
50 lM; dF-dC, 10 nM; 3-AP, 150 nM) for 24 h. Values relative to mean ara-
CTP amounts in ara-C-treated SAMHD1+/+ THP-1 cells shown (indicated by
dashed line). Circles, columns and error bars correspond to individual
values, means and SEM of at least three experiments performed
independently. Analyses were performed using unpaired two-tailed t-tests.
*P < 0.05; **P < 0.01.
C Quantification of dCK phosphorylation at serine-74 (S74) with respect to
total dCK in SAMHD1+/+ THP-1 cells treated with either solvent, 500 nM
ara-C or a combination of 500 nM ara-C and an RNRi (HU, 50 lM; dF-dC,
10 nM; 3-AP, 150 nM) for 24 h. Circles and squares, columns and error bars
correspond to individual measurements, means and SEM of one
representative out of two independent experiments performed in
triplicates. Statistical analyses were performed using unpaired two-tailed
t-test. *P < 0.05; **P < 0.01.
D Measurement of released inorganic triphosphate (PPPi) from hydrolysis of
ara-CTP (200 lM) by recombinant SAMHD1 (0.35 lM) in the presence of
GTP (200 lM) and a titration of different non-hydrolysable dNTP analogues
(dNTPaS) in the enzyme-coupled malachite green assay. Error bars indicate
SEM of two independent experiments performed in triplicate and
quadruplet.
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activator itself, and thus, ara-CTP hydrolysis is absolutely depen-
dent upon the existing intracellular dNTP pool. We propose a model
in which inhibition of RNR leads to a dNTP pool imbalance resulting
in a switch in the dNTP occupying the AS2 site of SAMHD1, leading
to reduced ara-CTPase activity (Fig EV5H). In support of this, firstly,
we show that the direct effect of sub-toxic concentrations of RNRi in
cultured cells causes significant imbalances of dNTP pools, rather
than uniform depletion, in particular the inversion of the dCTP-to-
dATP ratio. This is consistent with a previously reported fourfold to
fivefold increased dCTP-to-dATP ratio in HU-treated cells (Julias &
Pathak, 1998). Even though in vitro inhibition of RNR causes a
uniform reduction of all four NDPs (Chimploy et al, 2000), inhibi-
tion of RNR in cells does not lead to uniform dNTP depletion, but
rather to net pool imbalances. Specifically, purine dNTP pools are
consistently depleted but pyrimidine dNTP pools are much less
affected or even expanded (Snyder, 1984; Ahmad et al, 2017; Le
et al, 2017). With regard to dCTP, whilst RNR inhibition results in a
decrease in the de novo dCTP pool, generation of dCTP through
salvage pathways can simultaneously increase, thus resulting in a
net elevation of dCTP (Le et al, 2017). Accordingly, HU treatment
has been reported to lead to increased activity of the salvage path-
way enzymes thymidine kinase and dCK (Gao et al, 1995), and in
support of this, here, we show that RNRi treatment increased phos-
phorylation of dCK at S74, known to lead to increased selectivity
towards dC resulting in elevated dCTP salvage pools (Bunimovich
et al, 2014; Le et al, 2017). DCK activation, which would increase
the first intracellular phosphorylation step also for ara-C, might also
explain additive effects of RNRi and ara-C observed in cells devoid
of catalytically active SAMHD1. This is also consistent with a trend
towards prolonged survival in the two SAMHD1-negative AML
mouse models tested when comparing ara-C only with combined
ara-C/HU treatment.
The three RNRi shown here to synergise with ara-C in a
SAMHD1-dependent manner have distinct inhibitory mechanisms.
HU scavenges the free tyrosyl radical in the active site of RRM2 and
depletes the di-iron centre required for catalysis (Yarbro, 1992;
Nyholm et al, 1993), whilst 3-AP forms a complex with Fe2+ and
interferes with the regeneration of RRM2 tyrosyl radical (Aye et al,
2012). In contrast, dF-dC is a suicide inhibitor, becoming covalently
linked to the large RRM1 subunit (Wang et al, 2007). Interestingly,
none of the tested purine nucleoside RNRi, which bind to the allos-
teric site on RRM1, synergised with ara-C in a SAMHD1-dependent
manner. This discrepancy could be consistent with a time-depen-
dent loss of RNR inhibitory activity of both Cl-F-ara-A di- and
triphosphate (Aye & Stubbe, 2011) that is not observed for dF-dC
diphosphate (Wang et al, 2007). More importantly, in contrast to
non-allosteric HU and dF-dC (Gandhi et al, 1995; Smid et al, 2001;
Guo et al, 2016), purine RNRi are reported to strongly reduce dCTP
levels, and, consequently, dCTP-dATP ratios are not reversed (Sato
et al, 1984; Griffig et al, 1989; Parker et al, 1991; Xie & Plunkett,
1996). However, further studies are needed to elucidate why allos-
teric purine nucleoside RNRi do not synergise with ara-C in a
SAMHD1-dependent manner.
For cells expressing catalytically competent SAMHD1, we
propose that the relative increase of dCTP, particularly in propor-
tion to dATP, which is expected to typically occupy the AS2 site
of SAMHD1 in unperturbed cells (Koharudin et al, 2014), could
result in an increase of dCTP bound to this site. This shift might
further be favoured by the fact that the affinity to AS2 is reported
to be highest for dCTP, with a twofold, threefold and 10-fold
lower apparent Km as compared to dGTP, dATP and dTTP, respec-
tively (Jang et al, 2016). In addition, the lifetime of dCTP-induced
tetramers is reported to be longer than the one of its dATP-
induced counterparts (Wang et al, 2016). Secondly, in support of
our model, we show that whilst allosteric activation of SAMHD1
with non-hydrolysable derivatives of dATP, dGTP and dTTP led to
robust hydrolysis of ara-CTP in vitro, ara-CTPase activity is not
detected when using the dCTP derivative, even though dCTP-acti-
vated SAMHD1 is clearly able to hydrolyse dCTP. This is consis-
tent with the apparent lack of ara-CTPase activity in RNRi-treated
cells and patient-derived AML blasts. In line with this, it has been
previously demonstrated that dCTP as an AS2 activator can affect
SAMHD1 substrate specificity (Jang et al, 2016; Wang et al, 2016).
Nevertheless, future work will have to provide direct evidence for
this model. That, under certain circumstances, SAMHD1 can have
differential substrate specificity is illustrated by the fact that high
SAMHD1 expression in macrophages leads to consistent reduction
of dATP, dGTP, dCTP and dTTP, whilst dUTP levels remain high
—even though dUTP is a strong allosteric activator of SAMHD1
itself (Kennedy et al, 2011; Hansen et al, 2014). Different allosteric
activators can retain the overall structural properties of tetrameric
SAMHD1, but subtle conformational changes can be induced; for
example, the histidine-215 side chain in the catalytic site of
SAMHD1 is positioned differently in GTP:dATP SAMHD1 as
compared to dGTP:dATP SAMHD1 (Koharudin et al, 2014). Thus,
future efforts to resolve the co-crystals of ara-CTP bound SAMHD1
with different allosteric activators could shed light on the phenom-
enon described here.
Intricate interplay between RNR and SAMHD1, both allosterically
regulated by nucleotides and key enzymes in DNA precursor meta-
bolism, is perhaps to be expected, and this will undoubtedly have
relevance to the metabolism of nucleoside-based drugs. Consistent
with that notion, certain RRM1 single nucleotide polymorphisms
(SNPs) were reported to be associated with reduced ara-CTP accu-
mulation in ara-C-treated primary patient AML blasts, as well as
worse survival (Cao et al, 2013). Furthermore, here we show that
taking into account RRM1, RRM2 or RRM2B expression in a multi-
variable model leads to increased HRs for SAMHD1.
Whilst the precise molecular mechanism by which dNTP imbal-
ances resulting from RNR inhibition reduce SAMHD1 ara-CTPase
activity remains to be fully elucidated, the implications of this
phenomenon have immediate clinical impact. Critically, combina-
tions of ara-C and non-allosteric RNRi for AML and other haemato-
logical malignancies could be implemented directly in current
clinical practice, with SAMHD1 expression being a predictive
biomarker for therapeutic efficacy. HU/ara-C combinations have
been tested in early clinical trials with encouraging toxicity results
(Sauer et al, 1976; Howell et al, 1982; Tanaka et al, 1985; Zittoun
et al, 1985; Schilsky et al, 1987, 1992; Slapak et al, 1992; Frenette
et al, 1995; Higashigawa et al, 1997; Yee et al, 2006; Dubowy
et al, 2008; Odenike et al, 2008) (for further detail, see
Appendix Table S4). Furthermore, HU is amongst the cheapest drugs
used in oncology, and combinations with ara-C are thus not
restricted to developed countries. Indeed, overcoming the SAMHD1-
mediated barrier to ara-C efficacy that is responsible for worse OS in
AML (Herold et al, 2017b; Rassidakis et al, 2018) is particularly
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relevant for developing countries as they carry the major disease
burden and death toll of AML (Ferlay et al, 2015).
Combination chemotherapy is the paradigm of systemic anti-
cancer therapy, and effective combinations to date have largely been
identified empirically. Our study presents a new mechanistic ratio-
nale for a combination treatment with cytotoxic drugs being supe-
rior to single-agent treatments. Put into a broader perspective,
future work should systematically interrogate the underlying mecha-
nistic basis for clinical efficacy of commonly used combination
chemotherapies. Accordingly, combination chemotherapies could be
tailored and become part of personalised precision medicine that
hitherto has primarily focused on defined molecular targets (Chae
et al, 2017).
Materials and Methods
Human cell lines
THP-1, HuT-78, in vivo adapted HL-60 (HL-60/iva) (Herold et al,
2017b) and their CRISPR/Cas9-generated derivatives, described
previously (Herold et al, 2017b) or below, were cultured in Iscove’s
modified Dulbecco’s medium (IMDM; GE Healthcare). KBM-7,
K562, CCRF-CEM, MV-4-11, Jurkat and MOLT-4 were cultured in
Roswell Park Memorial Institute medium (RPMI 1640 GlutaMAX;
Thermo Fisher Scientific). All media were supplemented with 10%
heat-inactivated foetal calf serum (Thermo Fisher Scientific) and
100 U/ml penicillin–100 lg/ml streptomycin (Thermo Fisher Scien-
tific). Cell lines were purchased from ATCC except KBM-7 which
were a gift from Dr. Nina Gustafsson (Kancera AB & Karolinska
Institutet). All cell lines were regularly monitored and tested nega-
tive for the presence of mycoplasma using a commercial biochemi-
cal test (MycoAlert, Lonza). Cell line authentication was performed
by Eurofins Genomics Europe Applied Genomics GmbH (Ebersberg,
Germany) for luciferase-transduced SAMHD1-proficient and
SAMHD1-deficient THP-1 cell clones. DNA isolation was carried out
from cell pellet (cell layer). Genetic characteristics were determined
by PCR-single-locus-technology. Sixteen independent PCR systems
D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317,
D16S539, D2S1338, AMEL, D5S818, FGA, D19S433, vWA, TPOX
and D18S51 were investigated with proprietary primer sets. Cell
lines were typically cultured in densities between 1–10 × 105 cells/
ml at 37°C with 5% CO2 in a humidified incubator.
Generation of SAMHD1 CRISPR/Cas9 cell lines
Generation of THP-1 and HL-60/iva SAMHD1+/+ and SAMHD1/
cell clones was described previously (Herold et al, 2017b), referred
to as THP-1 ctrl, THP-1 g2-2, HL-60/iva g2-3 and HL-60/iva g2-2,
respectively (Herold et al, 2017b). Generation of firefly luciferase-
expressing THP-1 SAMHD1+/+ and SAMHD1/ cell clones has
been described (Herold et al, 2017c). Firefly luciferase-expressing
HL-60 SAMHD1+/+ and SAMHD1/ cells were generated similarly
by transducing HL-60 SAMHD1+/+ clone g2-3 and SAMHD1/
clone g2-2, respectively, with VSV-G pseudotyped lentiviral vector
expressing HA-LUC (pCSXW-HALUC), previously described (Herold
et al, 2017c). For reconstitution experiments, THP-1 SAMHD1/
cell clone g2-2 was transduced with VSV-G pseudotyped lentiviral
vector encoding gRNA-resistant SAMHD1 wild-type or catalytic-dead
mutant H233A, as described before (Herold et al, 2017a). THP-1
SAMHD1/ cell clone (g2-2) was transduced with VSV-G pseudo-
typed lentiviral vector encoding gRNA-resistant SAMHD1: either
wild-type or the phosphomutants T592A and T592E, as described
before (Herold et al, 2017a).
SAMHD1 CRISPR/Cas9 HuT-78 cell clones were generated by
transducing HuT-78 cells with CRISPR/Cas9 lentiviral vector encod-
ing gRNA g2 (Herold et al, 2017b). Cell bulks were selected with
puromycin for 2 weeks, and single cell clones were generated by
limiting dilution. As control, untransduced HuT-78 cell clones
(SAMHD1+/+) were generated in parallel.
Oligonucleotides encoding for SAMHD1 gRNAs were cac
cgCTCGGGCTGTCATCGCAACG (fwd g2) and
aaacCGTTGCGATGACAGCCCGAGc (rev g2), as well as cacc
gATCGCAACGGGGACGCTTGG (fwd g3)
and aaacCCAAGCGTCCCCGTTGCGATc (rev g3).
Production of VLPs
SIVMAC VLP production, either control or packaged with Vpx, was
described previously (Herold et al, 2017b) and references therein.
Primary AML blasts
Experiments with primary paediatric and adult AML blasts were
approved by the regional ethical review board in Stockholm (no. 03-
810, no. 02-445, no. 2013/1248-31/4 and no. 2013/1248-31/4), and
informed consent was obtained. Experiments conformed to the princi-
ples set out in the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report. Clinical and cytogenetic
parameters can be found in Appendix Table S2. Cells were thawed and
cultured at a density of 1 × 106 cells per ml in filtered StemPro-34 SFM
medium with StemPro Nutrient Supplement (cat no. 10639011;
Thermo Fisher Scientific), containing 10% foetal bovine serum (FBS;
GE Healthcare), 100 U/ml penicillin and 100 lg/ml streptomycin (cat
no. 15070063; Thermo Fisher Scientific). The medium was further
supplemented with the following recombinant cytokines in a concen-
tration of 20 ng/ml: IL-6 (cat no. 206-IL-010), IL-3 (cat no. 203-IL-010;
both R&D Systems), TPO (cat no. 02822) and GM-CSF (cat no.
78015.1; both Stemcell Technologies).
For Vpx treatment, 24 h after thawing, 10 × 106 cells were
collected, spun down and resuspended in 2 ml medium. Cells were
equally distributed in 10 wells of a 24-well plate and were treated
with either 50 ll of Vpx-VLPs or 50 ll of control VLPs each (two
groups of five wells, 1 × 106 cells total for each treatment). Cells
were incubated for 3 h at 37°C prior to collection and pooling before
an additional 8.5 ml of medium was added to increase the final
volume to 10 ml and cell density of 0.5 × 106 per ml. Cells were
incubated overnight prior to further processing.
Compound preparation
Cytarabine (ara-C) was purchased from Jena Bioscience, Germany
(cat no. N-20307-5), and Sigma-Aldrich, Sweden (cat no. C1768),
gemcitabine (dF-dC; cat no. G6423), hydroxyurea (HU; cat no.
H8627), triapine (3-AP; cat no. SML0568), clofarabine (Cl-F-ara-A;
cat no. C7495), fludarabine (2-F-ara-A; cat no. F2773) and
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cladribine (2CdA; cat no. C4438), were purchased from Sigma-
Aldrich, Sweden, and MK-1775 (cat no. SC-483196) was
purchased from Santa Cruz Biotechnology, USA. Compounds were
typically prepared as 10–50 mM stock solutions in DMSO and
were stored at 20°C, with the exception of HU which was
prepared fresh. Alternatively, when not being used with liquid
handling equipment, ara-C and HU were prepared in water; no
difference in EC50 was observed between DMSO and water stocks.
N-acetyl cysteine (NAC; Sigma-Aldrich) was dissolved in 1 M
HEPES solution (Thermo Fisher Scientific) to a concentration of
0.5 M and pH adjusted to 7.2. Prior to use, this stock solution
was diluted to 5 mM in complete cell media.
Phenotypic screen
For the screen, the following compound libraries were used: Scilife-
lab Primary Screening set (30K), SelleckChem known tool cpds:
L1700, Tocris mini known tool cpds: #2890, Prestwick chemical lib:
PCL-1200. Assay plates were prepared by transferring 30 nl of
10 mM DMSO compound solutions and controls using acoustic
dispensing (Echo 550, Labcyte) to white 384-well assay plates
(Corning 3570). Compounds were placed in columns 1–22. Thirty
nanoliter DMSO (negative control) was placed in column 23, and
30 nl 205 mM Ara-C (positive control) was placed in column 24.
The plates were then heat-sealed using peelable aluminium seal
(Eppendorf, 0030127790) with a thermal microplate sealer
(PlateLoc, Agilent) and then stored at 20°C until use. On the day
of the experiment, the plates were allowed to thaw for 30 min
followed by a brief centrifugation step (1,000 g for 1 min) prior to
removal of the seal. The final compound concentration in the screen
was 10 lM, and the final DMSO concentration was 0.1%. The final
concentration of the positive control was 205 lM ara-C.
THP-1 SAMHD1+/+ cells were diluted with cell culture medium.
For experiments in the presence of ara-C at EC10, cells were treated
with ara-C to a final concentration of 400 nM. Next, 1,000 cells per
well were dispensed using a MultiDrop device (Thermo Fisher
Scientific) to the assay plates already containing the test
compounds; the final volume in the assay plates was 30 ll. The
plates with cells were placed in a plastic container with damp cloths
to create a humid atmosphere. The box was incubated for 72 h at
37°C, 5% CO2 in a humidified incubator. The plates were removed
from the incubator and were placed at room temperature for
~ 30 min to allow equilibration to room temperature. Next, 30 ll
CellTiter-Glo Luminescent Cell Viability Assay (G7573; Promega)
diluted with an equal volume of water was added to the plates. The
plates were placed on an orbital shaker for ~ 3 min and were then
incubated for at least 7 min prior to reading the luminesce using an
Envision plate reader (PerkinElmer).
Proliferation inhibition assays and drug synergy analysis
Compound dilution series in DMSO were dispensed into 384-well
plates using either an Echo 550 Liquid Handler (Labcyte) or a
D300e Digital Dispenser (Tecan). The DMSO volume was normal-
ised across the plate, not exceeding a total volume of 500 nl per
well. Shortly after, cells (1,000 cells per well in 50 ll
medium) were dispensed into these plates using a MultiDrop
(Thermo Fisher Scientific); typically, to facilitate cell dispensing,
FCS in cell medium was reduced to 5%. Plates were incubated in
a humidified chamber at 37°C with 5% CO2 for 72–96 h before
addition of 10 ll resazurin (Sigma-Aldrich, Sweden; cat no.
R7017; 0.06 mg/ml in PBS) and were further incubated for 6 h
before measurement of fluorescence at 530/590 nm (ex/em) using
a Hidex Sense Microplate Reader. Fluorescence intensity for each
well was normalised to the average of control wells on the same
plate containing cells with DMSO (100% viability control) and
medium with DMSO (0% viability control). The data were anal-
ysed using a four-parameter logistic model in Prism 7 (GraphPad
Software).
The proliferation inhibition assay used for the synergy study on
primary AML blasts and the small-molecule screen was performed
using the ATP-release assay CellTiter-Glo (cat no. G7573,
Promega) instead of the resazurin-based assay described above. The
experimental setup was similar to the resazurin assay with a few
exceptions. The dispensed volume of cells was 30 ll per well
containing 1,000 cells for experiments with cell lines and 15,000
cells for experiments using primary AML blasts (treated according
to primary AML blasts section). For the experiments with sub-lethal
dose of ara-C, the cells were treated with 266 or 400 nM ara-C prior
to dispensing the cells. After 72-h incubation as described above,
the plates were removed from the incubator and placed at room
temperature for ~ 30 min to allow equilibration to room tempera-
ture. Thirty microliter CellTiter-Glo diluted with an equal volume
of water was added to the plates using a MultiDrop. The plates were
placed on an orbital shaker for ~ 3 min and were then incubated for
at least 7 min prior to reading the luminesce using an Envision plate
reader (PerkinElmer).
For synergy experiments, compound dispensing was performed
exclusively with the Tecan D300e Digital Dispenser using the
Synergy Wizard in the D300e Control Software. Prior to these exper-
iments, single-compound concentration–response curves were
performed to determine the concentration range to be used in the
concentration–response matrix, ideally choosing a dilution series to
obtain a complete concentration–response curve with each
compound individually. Cells were added to plates containing
compound dilution series, and incubated for 72 h before measure-
ment of cell viability, with the exception of the experiment
performed in the cell line panel, which were incubated for 96 h. The
average relative cell viability measurement from duplicate wells for
the dose–response matrix was compiled into a data frame for analy-
sis in the R-package Synergyfinder (Yadav et al, 2015). A dose–
response landscape using the ZIP or HSA models was generated and
an average synergy score across the landscape calculated. The HSA
model defines synergy as a combinatorial effect that is larger than
the individual drug effect observed at the same concentration,
whilst the ZIP model combines the widely used Bliss independence
and Loewe additivity models into a response surface model that
uses a delta score to characterise synergy. The delta score, derived
from the ZIP method, denotes the percentage of proliferation inhibi-
tion observed over the expected response, with a score of 0, > 0 or
< 0 corresponding to zero interaction, synergy or antagonism,
respectively. Based upon the original study (Yadav et al, 2015), a
delta score > 5 was categorised as strong synergy, whilst < 5 was
categorised as strong antagonism. The excess over HSA score
denotes the sum of differences between the combination effect and
the expected highest single-agent effect.
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Orthotopic AML mouse models using human AML cell lines
All animal experiments were carried out as per guidelines from
Swedish animal welfare rules and regulations as stated by the
Swedish Board of Agriculture. Experimental protocols were
approved by the regional animal ethical committee in Stockholm
in compliance with EU directive 2010/63 and followed the guideli-
nes stated in ethical applications #N89/14 and 5718-2019. Mice
were housed in required controlled environmental condition with
food and water ad libitum. Sample sizes for animal studies were
based on our experiences (Herold et al, 2017b) and were estimated
to be 5–6 per group with a power of 0.8 and a significance level of
0.05, estimating a hypothetical difference in median survival of
20 days with an SD of 12 days upon successful intervention. To
make THP-1 and HL-60/iva orthotopic models, 5 million cells (ei-
ther THP-1 or HL-60/iva SAMHD1+/+ and SAMHD1/ cell clones
expressing firefly luciferase) in PBS were injected into NOD/SCID
IL2R/ female mice by tail vein injection. Later, mice were
randomly divided into four different groups: vehicle, ara-C, HU
and combination of ara-C and HU. Six days after cell injection,
vehicle or drugs (either alone or in combination) were injected by
intraperitoneal injections into the mice, once a day for five consec-
utive days (dose for THP-1 study: vehicle—NS, ara-C—100 mg/kg,
HU—75 mg/kg and ara-C—100 mg/kg + HU—75 mg/kg; for HL-
60/iva study: vehicle—NS, ara-C—50 mg/kg, HU—75 mg/kg and
ara-C—50 mg/kg + HU—75 mg/kg). An additional study was
performed comparing the effects of vehicle, ara-C, dF-dC and
combination of ara-C and dF-dC in the THP-1 model. dF-dC was
only administered on days 1 and 3 of the 5-day treatment, both as
a single treatment or in combination with ara-C (in the latter case,
ara-C was given alone on days 2, 4 and 5). Doses: vehicle—NS,
ara-C—100 mg/kg, dF-dC—20 mg/kg and ara-C—100 mg/kg + HU
—20 mg/kg. Tumour progression and metastasis were monitored
using bioluminescence IVIS imaging system using Caliper Spectrum
CT. Before taking images, 10 ll/g (D Luciferin sodium salt 15 mg/ml
in PBS; cat no. L9504; Sigma-Aldrich, USA) was injected into the
mice by intraperitoneal injection. High photon counts, external
multiple tumours, single big tumour, more than 15% body weight
loss or appeared sick was considered as study end-point. If animals
died from apparent treatment toxicity more than 2 weeks before
onset of leukaemic symptoms in the control group, animals were
censored. Pathological gross examination of lymph node tumour
and abnormalities in lung, liver, spleen, kidney, if any, was
recorded during autopsy.
Orthotopic immunocompetent murine AML mouse model
All mice were maintained in a specific pathogen-free condition in
the animal facility of Karolinska Institutet. Animal procedures
were performed with approval from the local ethics committee
(ethical number 1869). Twelve- to fourteen-week-old wild-type
CD45.2 C57BL/6J mice carrying the CD45.2 antigen in their leuco-
cytes were used for the transplantation of MLL-AF9 retrovirally
transduced CD45.1+ mouse AML cells. AML cells were generated
from a syngeneic CD45.2 C57BL/6J mouse as previously described
(Xiao et al, 2018). MLL-AF9 AML cells were expanded in culture
in the presence of IL-3 (5 ng/ml, R&D Systems) in RPMI + 10%
FBS, and 250,000 MLL-AF9-expressing AML cells were
intravenously transplanted into the non-irradiated CD45.2 C57BL/
6J mice. At 20 days post-AML cell injection, Ara-C (75 mg/kg;
Sigma-Aldrich) and hydroxyurea (HU, 75 mg/kg; Jena Bioscience)
either alone or in combination (Ara-C 75 mg/kg + HU 75 mg/kg)
were injected intraperitoneally once a day for five consecutive
days. The control group of the mice were injected with NS. The
AML progression and engraftment were monitored by analysis of
peripheral blood using a haematology analyser (Sysmex-XP300)
and flow cytometry. The onset of AML and survival rate of the
mice were assessed based on the general health condition (such as
slow movement, hunch back, paralysed leg) of the mice after
treatment.
Cellular thermal shift assay (CETSA)
Cells were treated with compounds at a density of 0.5 × 106 cells/
ml for the indicated time before collection and washing in PBS. Cell
pellets were resuspended in Tris-buffered saline (TBS) supple-
mented with protease inhibitor cocktail (cOmpleteTM, Mini, EDTA-
free Protease Inhibitor Cocktail; cat no. 04693159001; Roche), 60 ll
per 1 × 106 cells, and aliquoted in PCR strip tubes (1 × 106 cells per
tube). Samples were heated for 3 min at the indicated temperature
ranging from 38 to 60°C, followed by a 3-min incubation at room
temperature. Cells were lysed in three freeze-thawing cycles consist-
ing of a 3-min ethanol and dry ice bath, followed by a 3-min incuba-
tion at 37°C in a water bath; samples were vigorously mixed after
each cycle by vortexing. Lysates were centrifuged for 20 min at
17,000 g to pellet the denatured and aggregated protein, and 45 ll
of the supernatant was transferred to a new tube and 15 ll 4×
Laemmli Sample Buffer (Bio-Rad) supplemented with 100 mM DTT
was added prior to boiling. Following Western blot analysis, band
intensities were quantified using Image Studio Lite software (LI-COR
Bioscience) and normalised to a thermostable protein loading
control (either SOD-1 (Miettinen & Bjorklund, 2014) or NUDT5
(Page et al, 2018)) before plotting and curve fitting (Boltzmann
sigmoidal) using Prism 7 (GraphPad Software) to determine the
Tagg.
In situ chemical cross-linking
Cells at a density of 0.5 × 106 cells/ml were treated with
compounds for the indicated time before collection by centrifuga-
tion, washing in PBS, aliquoting into 1.5-ml tubes (1 × 106 cells per
tube) and pelleting by centrifugation. Chemical cross-linker disuc-
cinimidyl glutarate (DSG; cat no. 20593, Thermo Fisher Scientific)
was prepared fresh in anhydrite DMSO (cat no. 1029310161, Merck
Millipore) to a stock concentration of 25 mM. DSG stock was diluted
in PBS to the desired concentration (5–0.3 mM) and each cell pellet
resuspended in 50 ll followed by a 30-min incubation at room
temperature. The reaction was quenched with the addition of 1 ml
1M Tris–HCl pH 8, and samples were incubated for a further 30 min
at room temperature before collection by centrifugation (800 g for
5 min) and processing for Western blot analysis.
Primer extension assay for measurement of intracellular dNTPs
Cells at a density of 0.5 × 106 cells/ml were treated with
compounds for the indicated time prior to collection and PBS
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washing. Cellular dNTP levels were measured by HIV-1 RT-based
dNTP assay (Diamond et al, 2004). Briefly, cellular dNTPs were
extracted from cells by 60% methanol and dried. The dried dNTP
samples were blinded prior to resuspension and direct application
to the RT-based primer extension reaction, which determines the
amounts of dNTPs in the extracted samples. The dNTP amounts
were normalised by 1 × 106 cells. Four different 19-mer DNA
templates containing sequence variations (N) at the 50 end nucleo-
tide (50-NTGGCGCCCGAACAGGGAC-30) were individually annealed
to an 18-mer DNA primer (50-GTCCCTGTTCGGGCGCCA-30), which
was 32P-labelled at its 50 end (template: primer, 4:1). The nucleotide
at the 50 end of the primer determines the dNTP to be measured.
HPLC-MS/MS assay for measurement of intracellular dNTPs
and ara-CTP
To simultaneously quantify the intracellular dNTPs and ara-CTP, an
ion pair chromatography–tandem mass spectrometry method (Fro-
mentin et al, 2010) was applied, with modifications. HPLC separa-
tion and MS detection were performed on a Vanquish Flex system
(Thermo Scientific, Waltham, MA) coupled with a TSQ Quantiva
triple quadrupole mass spectrometer (Thermo Scientific, Waltham,
MA). Analytes were separated using a Kinetex XB-C18 column
(150 × 2.1 mm, 2.6 lm; Phenomenex, Torrance, CA) at a flow rate
of 250 ll/min, 40°C. Mobile phase A consisted of 2 mM of ammo-
nium phosphate monobasic and 3 mM of hexylamine and mobile
phase B consisted of acetonitrile. The LC gradient increased from 5
to 10% of mobile phase B in 15 min, 10 to 40% in 4 min and then
returned to the initial condition in 0.5 min. Selected reaction moni-
toring in both positive and negative modes (spray voltage: 3,200 V
[pos] or 2,500 V [neg]; sheath gas: 35 Arb; auxiliary gas: 20 Arb;
ion transfer tube temperature: 350°C; vaporiser temperature: 380°C)
was used to detect the targets: dATP (492 ? 136, pos), dGTP
(508 ? 152, pos), dCTP (466 ? 158.9, neg), TTP (481 ? 158.9,
neg) and ara-CTP (484 ? 112, pos). Extracted samples were recon-
stituted in 400 ll of mobile phase A. After filtered through 0.2 lm
membrane, 20 ll of filtrate was mixed with 10 ll of 13C- and 15N-
labelled dNTPs as internal standards and further diluted 5 times
before subjected to LC-MS analysis. Injection volume was 5 ll. Data
were collected and processed by Thermo Xcalibur 3.0 software. Cali-
bration curves were generated from standards by serial dilutions in
mobile phase A (dNTPs and ara-CTP 1.25–1,000 nM). The calibra-
tion curves had r2 value > 0.99. All the chemicals and standards are
analytical grade or higher and were obtained commercially from
Sigma-Aldrich (St. Louis, MO). Nucleotides were at least 98% pure.
Western blot analysis
Sample preparation, SDS–PAGE and Western blot analysis were
performed as described previously (Drakos et al, 2007; Herold et al,
2017b). The following primary antibodies were used in this study:
SAMHD1 (Bethyl, A303-691A, 1:2,000; Abcam, ab128107, 1:1,000;
Proteintech Group, 12586-1-AP, 1:1,000), SOD-1 (Santa Cruz, sc-
11407, 1:3,000), RRM1 (Proteintech Group, 60073-2-1G, 1:1,000),
RRM2 (Sigma-Aldrich, WH0006241M1, 1:1,000), RRM2B (Abcam,
ab8105, 1:1,000), NUDT5 (in-house (Page et al, 2018), 1:1,000),
Chk1-pS345 (Cell Signaling, 2341, 1:750), Chk2-pT68 (Cell Signal-
ing, 2661, 1:750), Cleaved-PARP (Cell Signaling, 9541, 1:1,000),
cH2A.x (Millipore, 05-636, 1:2,000) and b-actin (Abcam, ab6276,
1:5,000; Santa Cruz, sc-47778 HRP, 1:2,000).
Enzyme-coupled SAMHD1 activity assay
Production of recombinant human SAMHD1 and Escherichia coli
inorganic pyrophosphatase (PPase), together with the assay
method, was described previously (Herold et al, 2017b). All (d)
NTPs and their analogues were purchased from Jena Biosciences.
Differential scanning fluorimetry
Differential scanning fluorimetry was performed as described before
(Valerie et al, 2016). Briefly, recombinant SAMHD1 protein (5 lM),
Sypro Orange (5X; Thermo Fisher Scientific), and DMSO or nucleo-
tides of various concentrations were combined in assay buffer (12.5
mM Tris-acetate, pH 7.5, 20 mM NaCl, 0.5 mM MgAc, 0.25 TCEP) in
96-well PCR plates at the final volume of 20 ll/well and DMSO
concentration of 1%. The assay mixture was then subject to a 25–
95°C temperature gradient with fluorescence intensities measured
every minute, on a LightCycler 480 Instrument II (Roche). Melting
temperatures were determined by LightCycler 480 Software.
Statistical methods
The distributions of mRNA levels of SAMHD1, RRM1, RRM2 and
RRM2B in the TARGET and TCGA AML patient cohorts were evalu-
ated using histograms and normal qq-plots. A natural log transfor-
mation was used for all four variables. Cox proportional hazards
models were used to estimate HR for death (OS) or event (EFS),
along with P-values and 95% confidence intervals. The proportional
hazards assumption (PHA) was assessed by plotting Schoenfeld
residuals against (a log transformation of) time and testing devia-
tions from a zero slope. No deviation from the PHA was detected.
Statistical analysis was carried out using R version 3.3.1 (R Founda-
tion for Statistical Computing, Vienna, Austria).
Pearson and Spearman correlations, Kaplan–Meier survival anal-
yses using Mantel–Cox log-rank test for animal studies, as well as
unpaired two-sided t-tests and ANOVAs, were all performed using
Prism 7 (GraphPad Software). Statistical analyses for relevant exper-
iments were performed using Prism 7 software (GraphPad). Statisti-
cal parameters for main figures are listed below; for supplemental
figures, see legends. For comparison of drug synergy scores, statisti-
cal significance was determined using a two-tailed unpaired t-test
(Fig 1E—for HU: THP-1 +/+ vs /, n = 7, P = < 0.0001, t = 6.09,
df = 12; THP-1 WT vs H233A, n = 6, P=< 0.0001, t = 7.711,
df = 10; HuT-78 +/+ vs /, n = 6, P = 0.0140, t = 2.972, df = 10;
HL-60 +/+ vs /, n = 7, P = 0.0038, t = 3.577, df = 12. For dF-
dC: THP-1 +/+ vs /, n = 6, P = 0.002, t = 4.065, df = 10; THP-1
WT vs H233A, n = 5, P = 0.0015, t = 4.707, df = 8; HuT-78 +/+ vs
/, n = 5, P = 0.0130, t = 3.178, df = 8; HL-60 +/+ vs /, n = 5,
P = 0.0379, t = 2.484, df = 8. For 3-AP: THP-1 +/+ vs /, n = 4,
P = 0.0004, t = 7.208, df = 6; THP-1 WT vs H233A, n = 4,
P = < 0.0001, t = 13.53, df = 6; HuT-78 +/+ vs /, n = 4 and 3,
respectively, P = 0.0007, t = 7.468, df = 5; HL-60 +/+ vs /,
n = 4, P = 0.3754, t = 0.9573, df = 6). For Kaplan–Meier analyses,
statistical significance was determined using Mantel–Cox log-rank
test (Fig 2A—for SAMHD1+/+: vehicle vs HU, n = 5 and 6, respec-
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tively, P = 0.9486, v2 = 0.004149, df = 1; vehicle vs ara-C, n = 5
and 6, respectively, P = 0.3173, v2 = 1, df = 1; vehicle vs ara-
C + HU, n = 5 and 3, respectively, P = 0.0082, v2 = 7, df = 1; HU
vs ara-C + HU, n = 6 and 3, respectively, P = 0.0079, v2 = 7.059,
df = 1; ara-C vs ara-C + HU, n = 5 and 3, respectively, P = 0.0141,
v
2
= 6.028, df = 1. For SAMHD1/: vehicle vs ara-C, n = 6,
P = 0.0012, v2 = 10.48, df = 1. Fig 2B—for SAMHD1+/+: vehicle
vs HU, n = 6, P = 0.5999, v2 = 0.2752, df = 1; vehicle vs ara-C,
n = 6, P = 0.1845, v2 = 1.761, df = 1; vehicle vs ara-C + HU,
n = 6, P = 0.0186, v2 = 5.542, df = 1; HU vs ara-C + HU, n = 6,
P = 0.0220, v2 = 5.248, df = 1; ara-C vs ara-C + HU, n = 6,
P = 0.0316, v2 = 4.619, df = 1. For SAMHD1/: vehicle vs ara-C,
n = 6, P = 0.0012, v2 = 10.56, df = 1. Fig 2C—vehicle vs ara-C:
n = 7, P = 0.6535, v2 = 0.2016, df = 1; vehicle vs dF-dC: n = 7 and
6, respectively, P = 0.0682, v2 = 3.326, df = 1; vehicle vs ara-
C + dF-dC: n = 7 and 6, respectively, P = 0.0011, v2 = 10.64,
df = 1; ara-C vs ara-C + dF-dC: n = 7 and 6, respectively,
P = 0.0014, v2 = 10.22, df = 1; dF-dC vs ara-C + dF-dC: n = 6,
P = 0.0097, v2 = 6.685, df = 1. Fig 2D—vehicle vs ara-C: n = 8 and
5, respectively, P = 0.0995, v2 = 2.713, df = 1; vehicle vs HU:
n = 8 and 5, respectively, P = 0.2184, v2 = 1.515, df = 1; vehicle
vs ara-C + HU: n = 8 and 5, respectively, P = 0.0026, v2 = 9.075,
df = 1). Statistical testing of paired drug synergy plots was deter-
mined using two-way ANOVA (Fig 3G—n = 12, F = 12.6, df = 1).
For statistical testing of dNTP pool ratios, unpaired two-tailed
t-tests were used (Fig 4A—HU vs. untreated: t = 11.27; df = 2;
P = 0.0078. 3-AP vs. untreated: t = 26.72; df = 2; P = 0.0014). For
statistical testing of ara-CTP levels, unpaired two-tailed t-tests were
used (Fig 4B—ara-C vs ara-C + HU: n = 3, P = 0.0162, t = 3.994,
df = 4; ara-C vs ara-C + dF-dC: n = 3, P = 0.0880, t = 2.246,
df = 4; ara-C vs ara-C + 3-AP: n = 3, P = 0.0463, t = 2.852, df = 4;
ara-C vs ara-C in THP-1 SAMHD1-/-: n = 3, P = 0.0014, t = 7.950,
df = 4). For statistical testing of dCK-S74 abundance, unpaired
two-tailed t-tests were used (Fig 4C—solvent vs HU: n = 3 and 6,
respectively, P = 0.0043, t = 4.141, df = 7; solvent vs dF-dC: n = 3,
P = 0.0034, t = 6.198, df = 4; solvent vs 3-AP: n = 3, P = 0.0160,
t = 4.009, df = 4).
Expanded View for this article is available online.
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The Paper Explained
Problem
The nucleoside analogue cytarabine (ara-C) is a cornerstone in the
treatment of acute myeloid leukaemia (AML), but resistance to this
drug will result in therapy failure and death. SAMHD1 is a dNTP
triphosphohydrolase that chemically inactivates the active triphos-
phate metabolite of ara-C. Thus, targeting SAMHD1 to enhance ara-C
efficacy is a rational strategy to improve survival in AML and other
haematological malignancies. However, to date, there are no clinically
viable strategies to achieve this.
Results
Using an unbiased phenotypic screening strategy, we identified clini-
cally used anti-cancer drugs—inhibitors of the nucleotide biosynthetic
enzyme ribonucleotide reductase (RNRi)—that can be used to indi-
rectly target the ara-CTP hydrolytic activity of SAMHD1. In various
AML models, including cultured cell lines, patient-derived AML blasts
and AML mouse models, we demonstrate that RNRi synergise with
ara-C in a manner that is dependent upon SAMHD1. Using biophysical
and biochemical methods, we propose a model in which nucleotide
pool imbalance resulting from inhibition of RNR perturbs the allos-
teric activation of SAMHD1, resulting in a reduction of ara-CTP
hydrolysis.
Impact
Combining ara-C with an RNRi promises to overcome SAMHD1-
mediated drug resistance in AML and other haematological malignan-
cies. At least two non-allosteric RNRi are FDA- and EMA-approved
and are currently employed in cancer treatment. In particular, hydrox-
yurea is an excellent candidate as it is affordable, as patents have
expired, and an indication in AML already exists. Thus, it is a prime
candidate for direct translation of our findings into clinical practice,
which can be achieved by adding moderate doses to each administra-
tion of ara-C when treating AML.
16 of 20 EMBO Molecular Medicine 12: e10419 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Sean G Rudd et al
and viewed by all authors. The project was supervised by SGR and NH.
CRISPR/Cas9 knockout cell lines and Vpx-VLPs were generated by JK, SSB
and TS Small-molecule screening strategy was conceived by NH, discussed
with TL and performed by HA. Concentration matrix drug synergy assays
were designed by SGR, CBJP and NH, method established by SGR and CBJP,
and subsequent experiments were performed by SGR, NT, CBJP, SMZ and
PM. Compound handling was performed by SGR, CBJP and EW. Cellular
thermal shift assays were designed by SGR and NH, method established by
SGR, NT and SL and subsequent experiments performed by NT and SGR.
Chemical cross-linking experiments were designed by SGR and NH and
performed by NT and SGR. Animal experiments were designed by SGR, KS,
UW-B, JW, HQ and NH and performed by KS, LS, SS, AR and HQ. DNA
damage signalling experiments were designed by SGR and performed by
SGR and NT. Experiments with primary patient-derived AML blasts were
designed and performed by SGR, NT, CBJP, NT, SöL, MH, DG, KPT, GR, HA
and NH. In vitro biochemical assays were designed by SGR, CBJP and NH
and performed SGR and CBJP. In vitro biophysical assays were designed by
SGR, SMZ and NH and performed by SMZ. Nucleotide pool measurement
experiments were designed by NH and SGR, samples prepared by SGR and
NT, and subsequent analysis performed by S’AC and ST under the supervi-
sion of BK and RFS. Experiments of dCK phosphorylation were planned by
RMB, JL and NH; samples were prepared by NT; and analyses were carried
out by GM and RMB. Analysis of TCGA and TARGET data was performed by
IHM and discussed with J-IH and NH. Funding for the project was acquired
by SGR, J-IH, TH and NH.
Conflict of interest
T.L. is employed at AstraZeneca. C.B.J.P is currently employed by Research
Institutes of Sweden.
For more information
(i) https://staff.ki.se/people/searud
(ii) https://staff.ki.se/people/nikher
References
Ahlmann M, Lanvers C, Lumkemann K, Rossig C, Freund A, Baumann M, Boos
J (2001) Modulation of ara-CTP levels by fludarabine and hydroxyurea in
leukemic cells. Leukemia 15: 69 – 73
Ahmad MF, Alam I, Huff SE, Pink J, Flanagan SA, Shewach D, Misko TA,
Oleinick NL, Harte WE, Viswanathan R et al (2017) Potent competitive
inhibition of human ribonucleotide reductase by a nonnucleoside small
molecule. Proc Natl Acad Sci USA 114: 8241 – 8246
Arnold LH, Groom HC, Kunzelmann S, Schwefel D, Caswell SJ, Ordonez P,
Mann MC, Rueschenbaum S, Goldstone DC, Pennell S et al (2015a)
Phospho-dependent regulation of SAMHD1 oligomerisation couples
catalysis and restriction. PLoS Pathog 11: e1005194
Arnold LH, Kunzelmann S, Webb MR, Taylor IA (2015b) A continuous enzyme-
coupled assay for triphosphohydrolase activity of HIV-1 restriction factor
SAMHD1. Antimicrob Agents Chemother 59: 186 – 192
Aye Y, Long MJ, Stubbe J (2012) Mechanistic studies of semicarbazone
triapine targeting human ribonucleotide reductase in vitro and in
mammalian cells: tyrosyl radical quenching not involving reactive oxygen
species. J Biol Chem 287: 35768 – 35778
Aye Y, Stubbe J (2011) Clofarabine 5’-di and -triphosphates inhibit human
ribonucleotide reductase by altering the quaternary structure of its large
subunit. Proc Natl Acad Sci USA 108: 9815 – 9820
Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93 – 141
Bhalla K, Swerdlow P, Grant S (1991) Effects of thymidine and hydroxyurea
on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in
highly resistant human leukemia cells. Blood 78: 2937 – 2944
Bunimovich YL, Nair-Gill E, Riedinger M, McCracken MN, Cheng D,
McLaughlin J, Radu CG, Witte ON (2014) Deoxycytidine kinase augments
ATM-Mediated DNA repair and contributes to radiation resistance. PLoS
ONE 9: e104125
Cao H (2004) Pharmacological induction of fetal hemoglobin synthesis using
histone deacetylase inhibitors. Hematology 9: 223 – 233
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME,
Hartford C, Raimondi S, Campana D et al (2013) RRM1 and RRM2
pharmacogenetics: association with phenotypes in HapMap cell lines and
acute myeloid leukemia patients. Pharmacogenomics 14: 1449 – 1466
Cerqueira NM, Fernandes PA, Ramos MJ (2007) Understanding ribonucleotide
reductase inactivation by gemcitabine. Chemistry (Weinheim an der
Bergstrasse, Germany) 13: 8507 – 8515
Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ (2017)
Path toward precision oncology: review of targeted therapy studies and
tools to aid in defining “actionability” of a molecular lesion and patient
management support. Mol Cancer Ther 16: 2645 – 2655
Chimploy K, Tassotto ML, Mathews CK (2000) Ribonucleotide reductase, a
possible agent in deoxyribonucleotide pool asymmetries induced by
hypoxia. J Biol Chem 275: 39267 – 39271
Chow KU, Boehrer S, Napieralski S, Nowak D, Knau A, Hoelzer D, Mitrou PS,
Weidmann E (2003) In AML cell lines Ara-C combined with purine
analogues is able to exert synergistic as well as antagonistic effects on
proliferation, apoptosis and disruption of mitochondrial membrane
potential. Leuk Lymphoma 44: 165 – 173
Colly LP, Richel DJ, Arentsen-Honders MW, Kester MG, ter Riet PM, Willemze
R (1992) Increase in Ara-C sensitivity in Ara-C sensitive and -resistant
leukemia by stimulation of the salvage and inhibition of the de novo
pathway. Ann Hematol 65: 26 – 32
De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a
comprehensive review and 2016 update. Blood Cancer J 6: e441
Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee
KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S et al (2004)
Macrophage tropism of HIV-1 depends on efficient cellular dNTP
utilization by reverse transcriptase. J Biol Chem 279: 51545 – 51553
Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff
M, Rassidakis GZ (2007) Inhibition of p53-murine double minute 2
interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and
apoptosis in Hodgkin lymphoma. Clin Cancer Res 13: 3380 – 3387
Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E,
Ravindranath Y, Camitta B (2008) Sequential oral hydroxyurea and
intravenous cytosine arabinoside in refractory childhood acute leukemia: a
pediatric oncology group phase 1 study. J Pediatr Hematol Oncol 30:
353 – 357
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F (2015) Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:
E359 – E386
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J,
Dewald GW, Ketterling RP, Bennett JM et al (2009) Anthracycline dose
intensification in acute myeloid leukemia. N Engl J Med 361: 1249 –
1259
Frenette PS, Desforges JF, Schenkein DP, Rabson A, Slapack CA, Miller KB
(1995) Granulocyte-macrophage colony stimulating factor (GM-CSF)
ª 2020 The Authors EMBO Molecular Medicine 12: e10419 | 2020 17 of 20
Sean G Rudd et al EMBO Molecular Medicine
priming in the treatment of elderly patients with acute myelogenous
leukemia. Am J Hematol 49: 48 – 55
Freund A, Boos J, Harkin S, Schultze-Mosgau M, Veerman G, Peters GJ,
Gescher A (1998) Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-
C) cytotoxicity in leukaemia cells by co-administration with antisignalling
drugs. Eur J Cancer 34: 895 – 901
Fromentin E, Gavegnano C, Obikhod A, Schinazi RF (2010) Simultaneous
quantification of intracellular natural and antiretroviral nucleosides and
nucleotides by liquid chromatography-tandem mass spectrometry. Anal
Chem 82: 1982 – 1989
Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B,
Chubb S, Hertel LW, Plunkett W (1995) Cytotoxicity, metabolism, and
mechanisms of action of 20 ,20-difluorodeoxyguanosine in Chinese hamster
ovary cells. Can Res 55: 1517 – 1524
Gandhi V, Plunkett W (1990) Modulatory activity of 20 ,20-
difluorodeoxycytidine on the phosphorylation and cytotoxicity of
arabinosyl nucleosides. Can Res 50: 3675 – 3680
Gao WY, Johns DG, Chokekuchai S, Mitsuya H (1995) Disparate actions of
hydroxyurea in potentiation of purine and pyrimidine 20 ,30-
dideoxynucleoside activities against replication of human
immunodeficiency virus. Proc Natl Acad Sci USA 92: 8333 – 8337
Griffig J, Koob R, Blakley RL (1989) Mechanisms of inhibition of DNA synthesis
by 2-chlorodeoxyadenosine in human lymphoblastic cells. Can Res 49:
6923 – 6928
Guo JR, Chen QQ, Lam CW, Wang CY, Wong VK, Chang ZF, Zhang W
(2016) Profiling ribonucleotide and deoxyribonucleotide pools perturbed
by gemcitabine in human non-small cell lung cancer cells. Sci Rep 6:
37250
Hansen EC, Seamon KJ, Cravens SL, Stivers JT (2014) GTP activator and dNTP
substrates of HIV-1 restriction factor SAMHD1 generate a long-lived
activated state. Proc Natl Acad Sci USA 111: E1843 – E1851
Heinemann V, Schulz L, Issels RD, Wilmanns W (1998) Regulation of
deoxycytidine kinase by deoxycytidine and deoxycytidine 50 triphosphate
in whole leukemia and tumor cells. Adv Exp Med Biol 431: 249 – 253
Herold N, Rudd S, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter
J-I, Schaller T (2017a) SAMHD1 protects cancer cells from various
nucleoside-based antimetabolites. Cell Cycle 16: 1029 – 1038
Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y,
Hagenkort A, Kutzner J, Page BD et al (2017b) Targeting SAMHD1 with the
Vpx protein to improve cytarabine therapy for hematological
malignancies. Nat Med 23: 256 – 263
Herold N, Rudd SG, Sanjiv K, Kutzner J, Myrberg IH, Paulin CBJ, Olsen TK,
Helleday T, Henter JI, Schaller T (2017c) With me or against me: tumor
suppressor and drug resistance activities of SAMHD1. Exp Hematol 52:
32 – 39
Higashigawa M, Hori H, Hirayama M, Kawasaki H, Ido M, Azuma E, Sakurai
M (1997) Salvage therapy for relapsed or refractory childhood acute
lymphocytic leukemia by alternative administration a lymphoid- and
myeloid-directed chemotherapeutic regimen consisting of dual
modulation of ara-C, hydroxyurea, and etoposide. Leuk Res 21: 811 – 815
Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, Goetze RW, Zhou L,
Nettles JH, Schinazi RF et al (2017) Substrates and Inhibitors of SAMHD1.
PLoS ONE 12: e0169052
Howell SB, Streifel JA, Pfeifle CE (1982) Modulation of the cellular
pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine.
Med Pediatr Oncol 10(Suppl 1): 81 – 91
Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava
S, Florens L, Washburn MP, Skowronski J (2011) Vpx relieves inhibition of
HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature
474: 658 – 661
Hubeek I, Peters GJ, Broekhuizen AJ, Kaspers GJ (2004) Modulation of
cytarabine induced cytotoxicity using novel deoxynucleoside analogs in
the HL60 cell line. Nucleosides, Nucleotides Nucleic Acids 23: 1513 – 1516
Iwasaki H, Huang P, Keating MJ, Plunkett W (1997) Differential incorporation
of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA
in proliferating human leukemia cells. Blood 90: 270 – 278
Jang S, Zhou X, Ahn J (2016) Substrate specificity of SAMHD1
triphosphohydrolase activity is controlled by deoxyribonucleoside
triphosphates and phosphorylation at Thr592. Biochemistry 55: 5635 – 5646
Ji X, Wu Y, Yan J, Mehrens J, Yang H, DeLucia M, Hao C, Gronenborn AM,
Skowronski J, Ahn J et al (2013) Mechanism of allosteric activation of
SAMHD1 by dGTP. Nat Struct Mol Biol 20: 1304 – 1309
Julias JG, Pathak VK (1998) Deoxyribonucleoside triphosphate pool imbalances
in vivo are associated with an increased retroviral mutation rate. J Virol
72: 7941 – 7949
Kennedy EM, Daddacha W, Slater R, Gavegnano C, Fromentin E, Schinazi RF,
Kim B (2011) Abundant non-canonical dUTP found in primary human
macrophages drives its frequent incorporation by HIV-1 reverse
transcriptase. J Biol Chem 286: 25047 – 25055
Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L,
Tofoleanu F, Reiss K, Ferreiros N, Geisslinger G et al (2018) The structural
basis for cancer drug interactions with the catalytic and allosteric sites of
SAMHD1. Proc Natl Acad Sci USA 115: E10022 – E10031
Koharudin LM, Wu Y, DeLucia M, Mehrens J, Gronenborn AM, Ahn J (2014)
Structural basis of allosteric activation of sterile alpha motif and
histidine-aspartate domain-containing protein 1 (SAMHD1) by nucleoside
triphosphates. J Biol Chem 289: 32617 – 32627
Kubota M, Takimoto T, Kitoh T, Tanizawa A, Akiyama Y, Kiriyama Y,
Mikawa H (1989) Ara-CTP metabolism following hydroxyurea or
methotrexate treatment in human leukemia cell lines. Adv Exp Med Biol
253b: 363 – 367
Kubota M, Takimoto T, Tanizawa A, Akiyama Y, Mikawa H (1988) Differential
modulation of 1-beta-D-arabinofuranosylcytosine metabolism by
hydroxyurea in human leukemic cell lines. Biochem Pharmacol 37:
1745 – 1749
Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E,
Yatim A, Emiliani S, Schwartz O, Benkirane M (2011) SAMHD1 is the
dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted
by Vpx. Nature 474: 654 – 657
Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas
D, Nikanjam M et al (2017) ATR inhibition facilitates targeting of leukemia
dependence on convergent nucleotide biosynthetic pathways. Nat
Commun 8: 241
Lowenberg B (2013) Sense and nonsense of high-dose cytarabine for acute
myeloid leukemia. Blood 121: 26 – 28
Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP,
Lazarus HM, Levine RL, Litzow MR, Paietta EM et al (2016) Benefit of
high-dose daunorubicin in AML induction extends across cytogenetic and
molecular groups. Blood 127: 1551 – 1558
Mamez AC, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, Schlemmer B,
Dombret H, Azoulay E, Lengline E (2016) Pre-treatment with oral
hydroxyurea prior to intensive chemotherapy improves early survival of
patients with high hyperleukocytosis in acute myeloid leukemia. Leuk
Lymphoma 57: 2281 – 2288
Mauney C, Rogers L, Harris R, Daniel L, Devarie-Baez N, Wu H, Furdui C,
Poole LB, Perrino F, Hollis T (2017) The SAMHD1 dNTP
18 of 20 EMBO Molecular Medicine 12: e10419 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Sean G Rudd et al
triphosphohydrolase is controlled by a redox switch. Antioxid Redox Signal
27: 1317 – 1331
Mauney CH, Perrino FW, Hollis T (2018) Identification of inhibitors of the
dNTP triphosphohydrolase SAMHD1 using a novel and direct high-
throughput assay. Biochemistry 57: 6624 – 6636
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA,
Moore JO, McIntyre OR, Frei E 3rd (1994) Intensive postremission
chemotherapy in adults with acute myeloid leukemia. Cancer and
Leukemia Group B. N Engl J Med 331: 896 – 903
Miettinen TP, Bjorklund M (2014) NQO2 is a reactive oxygen species
generating off-target for acetaminophen. Mol Pharm 11: 4395 – 4404
Nyholm S, Thelander L, Graslund A (1993) Reduction and loss of the iron
center in the reaction of the small subunit of mouse ribonucleotide
reductase with hydroxyurea. Biochemistry 32: 11569 – 11574
Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain
MJ, Stock W (2008) Phase I study of the ribonucleotide reductase inhibitor
3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in
combination with high dose cytarabine in patients with advanced
myeloid leukemia. Invest New Drugs 26: 233 – 239
O’Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG,
Tarassoff PG, Von Hoff DD (1994) Phase I clinical trial of gemcitabine
given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30a:
417 – 418
Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd
SG, Loseva O, Jemth AS, Almlof I et al (2018) Targeted NUDT5 inhibitors
block hormone signaling in breast cancer cells. Nat Commun 9: 250
Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW,
Shortnacy AT, Montgomery JA, Secrist JA 3rd, Bennett LL Jr (1991) Effects of
2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562
cellular metabolism and the inhibition of human ribonucleotide reductase
and DNA polymerases by its 5’-triphosphate. Can Res 51: 2386 – 2394
Patra KK, Bhattacharya A, Bhattacharya S (2019) Molecular dynamics
investigation of a redox switch in the anti-HIV protein SAMHD1. Proteins
87: 748 – 759
Plagemann PG, Marz R, Wohlhueter RM (1978) Transport and metabolism of
deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured
Novikoff rat hepatoma cells, relationship to phosphorylation, and
regulation of triphosphate synthesis. Can Res 38: 978 – 989
Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985)
Pharmacologically directed ara-C therapy for refractory leukemia. Semin
Oncol 12: 20 – 30
Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI,
Schaller T, Ng SB, Chng WJ, Yan B et al (2018) Low-level expression of
SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved
outcome upon consolidation chemotherapy with high-dose cytarabine-
based regimens. Blood Cancer J 8: 98
Rauscher F 3rd, Cadman E (1983) Biochemical and cytokinetic modulation of
L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-
arabinofuranosylcytosine metabolism and cytotoxicity. Can Res 43:
2688 – 2693
Rieber M, Rieber MS (1994) Cyclin-dependent kinase 2 and cyclin A
interaction with E2F are targets for tyrosine induction of B16 melanoma
terminal differentiation. Cell Growth Differ 5: 1339 – 1346
Rodriguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O, Agell N (2007)
Different S/M checkpoint responses of tumor and non tumor cell lines to
DNA replication inhibition. Can Res 67: 11648 – 11656
Rudd SG, Schaller T, Herold N (2017) SAMHD1 is a barrier to antimetabolite-
based cancer therapies. Mol Cell Oncol 4: e1287554
Santini V, D’Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi-Ferrini P
(1996) Effects of fludarabine and gemcitabine on human acute myeloid
leukemia cell line HL 60: direct comparison of cytotoxicity and cellular
Ara-C uptake enhancement. Leuk Res 20: 37 – 45
Sato A, Montgomery JA, Cory JG (1984) Synergistic inhibition of leukemia
L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides
and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole. Can Res 44:
3286 – 3290
Sauer H, Pelka R, Wilmanns W (1976) Pharmakokinetics of hydroxy-urea.
Therapy of acute myeoblastic leukemias using synchronization and
recruitment effects (author’ transl). Klin Wochenschr 54: 203 – 209
Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, Anderson J, Peterson BA
(1992) Laboratory and clinical studies of biochemical modulation by
hydroxyurea. Semin Oncol 19: 84 – 89
Schilsky RL, Williams SF, Ultmann JE, Watson S (1987) Sequential
hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin’s
lymphoma. J Clin Oncol 5: 419 – 425
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R,
Bohnenberger H, Kaderali L, Stegmann L, Cremer A et al (2016) SAMHD1 is
a biomarker for cytarabine response and a therapeutic target in acute
myeloid leukemia. Nat Med 23: 250 – 255
Seamon KJ, Hansen EC, Kadina AP, Kashemirov BA, McKenna CE, Bumpus NN,
Stivers JT (2014) Small molecule inhibition of SAMHD1 dNTPase by
tetramer destabilization. J Am Chem Soc 136: 9822 – 9825
Seamon KJ, Stivers JT (2015) A high-throughput enzyme-coupled assay for
SAMHD1 dNTPase. J Biomol Screen 20: 801 – 809
Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ (2007)
The synergistic interaction of gemcitabine and cytosine arabinoside with
the ribonucleotide reductase inhibitor triapine is schedule dependent.
Biochem Pharmacol 73: 1548 – 1557
Slapak CA, Desforges JF, Fogaren T, Miller KB (1992) Treatment of acute
myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea,
and calcitriol. Am J Hematol 41: 178 – 183
Smid K, Van Moorsel CJ, Noordhuis P, Voorn DA, Peters GJ (2001) Interference
of gemcitabine triphosphate with the measurements of deoxynucleotides
using an optimized DNA polymerase elongation assay. Int J Oncol 19:
157 – 162
Snyder RD (1984) Deoxyribonucleoside triphosphate pools in human diploid
fibroblasts and their modulation by hydroxyurea and deoxynucleosides.
Biochem Pharmacol 33: 1515 – 1518
Somyajit K, Gupta R, Sedlackova H, Neelsen KJ, Ochs F, Rask MB, Choudhary
C, Lukas J (2017) Redox-sensitive alteration of replisome architecture
safeguards genome integrity. Science 358: 797 – 802
Streifel JA, Howell SB (1981) Synergistic interaction between 1-beta-D-
arabinofuranosylcytosine, thymidine, and hydroxyurea against human B
cells and leukemic blasts in vitro. Proc Natl Acad Sci USA 78: 5132 – 5136
Stumpel DJPM, Schneider P, Pieters R, Stam RW (2015) The potential of
clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J
Cancer 51: 2008 – 2021
Tanaka M, Kimura K, Yoshida S (1985) Mechanism of synergistic cell killing by
hydroxyurea and cytosine arabinoside. Jpn J Cancer Res 76: 729 – 735
Tanguay DA, Chiles TC (1994) Cell cycle-specific induction of Cdk2 expression
in B lymphocytes following antigen receptor cross-linking. Mol Immunol
31: 643 – 649
Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of
gemcitabine in cancer therapy. Future Oncol (London, England) 1: 7 – 17
Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N (2018) Nucleobase and
nucleoside analogues: resistance and re-sensitisation at the level of
ª 2020 The Authors EMBO Molecular Medicine 12: e10419 | 2020 19 of 20
Sean G Rudd et al EMBO Molecular Medicine
pharmacokinetics, pharmacodynamics and metabolism. Cancers 10:
e10070240
Valerie NC, Hagenkort A, Page BD, Masuyer G, Rehling D, Carter M, Bevc L,
Herr P, Homan E, Sheppard NG et al (2016) NUDT15 hydrolyzes 6-thio-
DeoxyGTP to mediate the anticancer efficacy of 6-thioguanine. Can Res 76:
5501 – 5511
Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P,
Porter CC (2013) Inhibition of Wee1 sensitizes cancer cells to
antimetabolite chemotherapeutics in vitro and in vivo, independent of p53
functionality. Mol Cancer Ther 12: 2675 – 2684
Walsh CT, Craig RW, Agarwal RP (1980) Increased activation of 1-beta-D-
arabinofuranosylcytosine by hydroxyurea in L1210 cells. Can Res 40:
3286 – 3292
Wang J, Lohman GJ, Stubbe J (2007) Enhanced subunit interactions with
gemcitabine-50-diphosphate inhibit ribonucleotide reductases. Proc Natl
Acad Sci USA 104: 14324 – 14329
Wang Z, Bhattacharya A, Villacorta J, Diaz-Griffero F, Ivanov DN (2016)
Allosteric activation of SAMHD1 by deoxynucleotidetriphosphate (dNTP)-
dependent tetramerization requires dNTP concentrations that are similar
to dNTP concentrations observed in cycling T cells. J Biol Chem 291:
21407 – 21413
Wisitpitthaya S, Zhao Y, Long MJ, Li M, Fletcher EA, Blessing WA, Weiss RS,
Aye Y (2016) Cladribine and fludarabine nucleotides induce distinct
hexamers defining a common mode of reversible RNR inhibition. ACS
Chem Biol 11: 2021 – 2032
Xiao P, Sandhow L, Heshmati Y, Kondo M, Bouderlique T, Dolinska M,
Johansson AS, Sigvardsson M, Ekblom M, Walfridsson J et al (2018)
Distinct roles of mesenchymal stem and progenitor cells during the
development of acute myeloid leukemia in mice. Blood Adv 2: 1480 – 1494
Xie KC, Plunkett W (1996) Deoxynucleotide pool depletion and sustained
inhibition of ribonucleotide reductase and DNA synthesis after treatment
of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-
arabinofuranosyl) adenine. Can Res 56: 3030 – 3037
Yadav B, Wennerberg K, Aittokallio T, Tang J (2015) Searching for drug
synergy in complex dose-response landscapes using an interaction
potency model. Comput Struct Biotechnol J 13: 504 – 513
Yan J, Hao C, DeLucia M, Swanson S, Florens L, Washburn MP, Ahn J,
Skowronski J (2015) CyclinA2-cyclin-dependent kinase regulates
SAMHD1 protein phosphohydrolase domain. J Biol Chem 290:
13279 – 13292
Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19:
1 – 10
Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W,
Thomas D, Faderl S, King I, O’Brien SM et al (2006) Triapine and
cytarabine is an active combination in patients with acute leukemia or
myelodysplastic syndrome. Leuk Res 30: 813 – 822
Zhu CF, Wei W, Peng X, Dong YH, Gong Y, Yu XF (2015) The mechanism of
substrate-controlled allosteric regulation of SAMHD1 activated by GTP.
Acta Crystallogr D Biol Crystallogr 71: 516 – 524
Zittoun R, Marie JP, Zittoun J, Marquet J, Haanen C (1985) Modulation of
cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia. Semin
Oncol 12: 139 – 143
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
20 of 20 EMBO Molecular Medicine 12: e10419 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Sean G Rudd et al
